{"count":325,"next":"https://lda.gov/api/v1/filings/?filing_specific_lobbying_issues=S.+2&filing_year=2026&ordering=-filing_year&page=2","previous":null,"results":[{"url":"https://lda.gov/api/v1/filings/576e0cde-e9f2-498f-9e62-6c998ca3bd71/","filing_uuid":"576e0cde-e9f2-498f-9e62-6c998ca3bd71","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/576e0cde-e9f2-498f-9e62-6c998ca3bd71/print/","filing_document_content_type":"text/html","income":"30000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Zach Price","dt_posted":"2026-04-01T12:47:33-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"505 9th Street NW","registrant_address_2":"Suite 830","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":294930,"url":"https://lda.gov/api/v1/registrants/294930/","house_registrant_id":37434,"name":"THE WASHINGTON TAX & PUBLIC POLICY GROUP (FORMERLY THE WASHINGTON TAX GROUP)","description":"​Legislative and regulatory consulting.","address_1":"505 9th Street NW","address_2":"Suite 830","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GREGORY NICKERSON","contact_telephone":"+1 202-534-4949","dt_updated":"2026-10-16T16:30:45.569326-04:00"},"client":{"id":178980,"url":"https://lda.gov/api/v1/clients/178980/","client_id":294966,"name":"THE GOODYEAR TIRE & RUBBER COMPANY","general_description":"Tire manufacturer","client_government_entity":false,"client_self_select":false,"state":"OH","state_display":"Ohio","country":"US","country_display":"United States of America","ppb_state":null,"ppb_state_display":null,"ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2008-11-01"},"lobbying_activities":[{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to corporate and international tax. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 951A, 163(j), 41, 38(c)(1), and 174. Issues related to retreaded tires. (H.R. 3401 and S. 2790)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":38177,"prefix":null,"prefix_display":null,"first_name":"GREGORY","nickname":null,"middle_name":null,"last_name":"NICKERSON","suffix":null,"suffix_display":null},"covered_position":"Staff Dir., Ways&Means Subcom. on Select Reven.","new":false},{"lobbyist":{"id":69617,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":"AUSTIN","last_name":"PRICE","suffix":null,"suffix_display":null},"covered_position":"Staff assistant to Sen. Coats.","new":false},{"lobbyist":{"id":149073,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"MAX","last_name":"PEDROTTI","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Deputy Chief of Staff to Rep. Carol Miller","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues related to USMCA and global tire supply chains.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69617,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":"AUSTIN","last_name":"PRICE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/db1f371b-cede-4e34-8f17-afbf098be9bb/","filing_uuid":"db1f371b-cede-4e34-8f17-afbf098be9bb","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/db1f371b-cede-4e34-8f17-afbf098be9bb/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Zach Price","dt_posted":"2026-04-01T12:56:06-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"505 9th Street NW","registrant_address_2":"Suite 830","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":294930,"url":"https://lda.gov/api/v1/registrants/294930/","house_registrant_id":37434,"name":"THE WASHINGTON TAX & PUBLIC POLICY GROUP (FORMERLY THE WASHINGTON TAX GROUP)","description":"​Legislative and regulatory consulting.","address_1":"505 9th Street NW","address_2":"Suite 830","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GREGORY NICKERSON","contact_telephone":"+1 202-534-4949","dt_updated":"2026-10-16T16:30:45.569326-04:00"},"client":{"id":56815,"url":"https://lda.gov/api/v1/clients/56815/","client_id":56815,"name":"KENVUE INC.","general_description":"Consumer health.","client_government_entity":null,"client_self_select":false,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-07-01"},"lobbying_activities":[{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to corporate and international tax. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 163(j), 951A, 250, and 174. (H.R. 8101, S. 4221).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":38177,"prefix":null,"prefix_display":null,"first_name":"GREGORY","nickname":null,"middle_name":null,"last_name":"NICKERSON","suffix":null,"suffix_display":null},"covered_position":"Tax Counsel, Ways and Means Committee; Staff Director, Ways and Means Select Revenue Measures Subcommittee","new":false},{"lobbyist":{"id":69617,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":"AUSTIN","last_name":"PRICE","suffix":null,"suffix_display":null},"covered_position":"Staff Assistant to Sen. Coats","new":false},{"lobbyist":{"id":149073,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"MAX","last_name":"PEDROTTI","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Deputy Chief of Staff to Rep. Carol Miller","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/0944fcd0-c90f-497b-9066-9eee90bb55fc/","filing_uuid":"0944fcd0-c90f-497b-9066-9eee90bb55fc","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/0944fcd0-c90f-497b-9066-9eee90bb55fc/print/","filing_document_content_type":"text/html","income":"430000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Zach Price","dt_posted":"2026-04-01T13:21:21-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"505 9th Street NW","registrant_address_2":"Suite 830","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":294930,"url":"https://lda.gov/api/v1/registrants/294930/","house_registrant_id":37434,"name":"THE WASHINGTON TAX & PUBLIC POLICY GROUP (FORMERLY THE WASHINGTON TAX GROUP)","description":"​Legislative and regulatory consulting.","address_1":"505 9th Street NW","address_2":"Suite 830","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GREGORY NICKERSON","contact_telephone":"+1 202-534-4949","dt_updated":"2026-10-16T16:30:45.569326-04:00"},"client":{"id":178996,"url":"https://lda.gov/api/v1/clients/178996/","client_id":295157,"name":"TAX REFORM COALITION","general_description":"Coalition of companies with an interest in corporate tax reform","client_government_entity":false,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":null,"ppb_state_display":null,"ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2013-08-27"},"lobbying_activities":[{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on financial reporting and on the tax base of the U.S. Issues related to IRC sections 11, 41 and 174, 55, 56A, and 59, 59A, 163(j), 250, 951A, 954(d) and 954(e), and 960(d)(2). (S. 1605, S. 2976, H.R. 8101, S. 4221)","foreign_entity_issues":"Bayer Corporation, a New Jersey corporation, is a wholly owned subsidiary of Bayer AG, a German corporation.","lobbyists":[{"lobbyist":{"id":38177,"prefix":null,"prefix_display":null,"first_name":"GREGORY","nickname":null,"middle_name":null,"last_name":"NICKERSON","suffix":null,"suffix_display":null},"covered_position":"Staff Dir., Ways&Means Subcom. on Select Reven.","new":false},{"lobbyist":{"id":69617,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":"AUSTIN","last_name":"PRICE","suffix":null,"suffix_display":null},"covered_position":"Staff assistant to Sen. Coats.","new":false},{"lobbyist":{"id":149073,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"MAX","last_name":"PEDROTTI","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Deputy Chief of Staff to Rep. Carol Miller","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/db9eadc1-42de-444d-85eb-7d9478453c88/","filing_uuid":"db9eadc1-42de-444d-85eb-7d9478453c88","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/db9eadc1-42de-444d-85eb-7d9478453c88/print/","filing_document_content_type":"text/html","income":null,"expenses":"75000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Maynard Friesz","dt_posted":"2026-04-01T21:02:59-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"50 Commerce Dr","registrant_address_2":"Suite 90","registrant_different_address":true,"registrant_city":"Schaumburg","registrant_state":"IL","registrant_zip":"60173","registrant":{"id":401104586,"url":"https://lda.gov/api/v1/registrants/401104586/","house_registrant_id":null,"name":"CURE SMA","description":"Non-profit","address_1":"50 Commerce Dr","address_2":"Suite 90","address_3":null,"address_4":null,"city":"Schaumburg","state":"IL","state_display":"Illinois","zip":"60173","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MAYNARD FRIESZ","contact_telephone":"+1 202-871-8004","dt_updated":"2026-07-10T12:05:55.658081-04:00"},"client":{"id":202103,"url":"https://lda.gov/api/v1/clients/202103/","client_id":12,"name":"CURE SMA","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"IL","state_display":"Illinois","country":"US","country_display":"United States of America","ppb_state":"IL","ppb_state_display":"Illinois","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-08-28"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Research into spinal muscular atrophy, timely access to care, treatments, medical devices, and home and community-based services, Give Kids a Chance Act (H.R.1261/ S.932- FDA Pediatric Priority Review Voucher Program), DOD Congressionally Directed Medical Research Program & Peer-Reviewed Medical Research Program, Labor-Health and Human Services, and Education Appropriations bill, Family Caregiver Awareness, Resources, and Education (CARE) Partnerships Act, Pediatric Palliative Care Homes, National Institute on Disability, Independent Living, and Rehabilitation Research funding, Seat Elevation in Group 2 Non-Complex Power Wheelchairs, Coverage of Standing Systems in Group 3 Power Wheelchair, Competitive Bidding for Tracheostomy, Ostomy and Urological Supplies; FDA Rare Disease Patient Listening Session, Coverage of Respiratory Assist Devices (RADs) and Home Mechanical Ventilators (HMVs), Accelerating Kids Access to Care Act (H.R. 1509/S. 752, National Institutes of Health funding; Medicaid home and community-based services, Public Law 119-21 Medicaid Community Engagement Requirements - disability and medically frail definition; Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343), Veterans STAND Act (H.R. 6835), Veterans SPORTS Act (S. 3138) Consolidated Appropriations Act of 2026 (P.L. 119-75)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"National Institutes of Health research into spinal muscular atrophy, U.S. Department of Defense Peer-Reviewed Medical Research in spinal muscular atrophy, Congressionally Directed Medical Research Program funding, Medicaid home and community-based services, housing (Sec. 811 Housing for People with Disabilities & Mainstream Housing Choice Vouchers), Defense Health Research Programs (Congressionally Directed Medical Research Programs), National Institute on Disability, Independent Living, and Rehabilitation Research funding, Labor-HHS-Education Appropriations bill, Transportation-HUD Appropriations bill, Defense Appropriations bill, Department of Education Office of Special Education and Rehabilitative Services staffing, Consolidated Appropriations Act of 2026 (P.L. 119-75), Assistive Technology Act program funding, Access Board funding","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":35,"name":"Housing & Urban Development, Dept of (HUD)"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":40,"name":"Transportation, Dept of (DOT)"}]},{"general_issue_code":"CIV","general_issue_code_display":"Civil Rights/Civil Liberties","description":"Supplemental Security Income Savings Penalty Elimination Act (H.R.2540/ S.1234), SSI Restoration Act, disability marriage penalty, Marriage Equality for Disabled Adults Act (H.R. 1389), Eliminating the Marriage Penalty in SSI Act (H.R. 320/ S.73), home and community-based services, Individuals with Disabilities Act (P.L. 101-336), ENABLE Act (H.R.1436/S.627), Seat Elevation in Group 2 Non-Complex Power Wheelchairs, Coverage of Standing Systems in Power Wheelchairs, Adult Changing Tables at U.S. Capitol, Department of Education Office of Special Education and Rehabilitative Services staffing and enforcement, Public Law 119-21 Implementation, including disability and medically frail definition for Medicaid Community Engagement Requirement; Veterans STAND Act (H.R. 6835), Veterans SPORTS Act (S. 3138), ABLE Tomorrow Act, the ABLE MATCH Act, and the ABLE Direct Deposit Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AVI","general_issue_code_display":"Aviation/Airlines/Airports","description":"FAA Reauthorization Act of 2024 (P.L. 118-63); Air Carrier Access Act (P.L. 99-435), Ensuring Safe Accommodations for Air Travelers with Disabilities Using Wheelchairs Final Rule, \"Ensuring Safe Accommodations for Air Travelers with Disabilities Using Wheelchairs Rule II, Transportation-HUD Appropriations bill, disability-related air travel complaints & aviation consumer protections","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":40,"name":"Transportation, Dept of (DOT)"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"U.S. Department of Defense Peer-Reviewed Medical Research Program Research in Spinal Muscular Atrophy, Funding for Defense Health Research Programs (Congressionally Directed Medical Research Programs and Peer Reviewed Medical Research Program), Medical Research for Our Troops Act (H.R. 3906)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HOU","general_issue_code_display":"Housing","description":"Transportation-HUD Appropriations bill, housing for people with disabilities (Sec. 811 Housing for People with Disabilities & Mainstream Housing Choice Vouchers), funding for disability and aging programs","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":35,"name":"Housing & Urban Development, Dept of (HUD)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"medical research in spinal muscular atrophy, development and approval of spinal muscular atrophy treatments, National Institutes of Health funding, U.S. Department of Defense peer reviewed research in spinal muscular atrophy, U.S. Department of Defense Congressionally Directed Medical Research Program funding, Medical Research for Our Troops Act (H.R. 3906)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicaid home and community-based services, Medicaid caregiving services, Medicaid funding, 2025 Budget Resolution, durable medical equipment, Pediatric Palliative Care Homes, H.R. 1, Think Differently Database Act (P.L. 118-225), Labor-HHS-Education Appropriations bill, Public Law 119-21 Implementation, including disability and medically frail definition for Medicaid Community Engagement Requirement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"ENABLE Act (H.R.1436/ S.627), Mobility Means Freedom Act (H.R.2320), Achieving a Better Life Experience (ABLE) Act (P.L. 113-295), H.R. 1, ABLE Tomorrow Act, the ABLE MATCH Act, and the ABLE Direct Deposit Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRA","general_issue_code_display":"Transportation","description":"FAA Reauthorization Act of 2024 (P.L. 118-63); Air Carrier Access Act (P.L. 99-435), Ensuring Safe Accommodations for Air Travelers with Disabilities Using Wheelchairs Final Rule, Disability Access to Transportation Act, accessibility in community transportation, Automated Vehicle (AV) Deployment and Research, Transportation-HUD Appropriations bill, surface transportation reauthorization","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":40,"name":"Transportation, Dept of (DOT)"}]},{"general_issue_code":"EDU","general_issue_code_display":"Education","description":"Labor, Health and Human Services, and Education Appropriations bill; IDEA Full Funding Act (H.R.2598/ S.1277), IDEA enforcement and oversight, Department of Education Office of Special Education and Rehabilitative Services staffing and enforcement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":32,"name":"Education, Dept of"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DIS","general_issue_code_display":"Disaster Planning/Emergencies","description":"Disaster Relief Medicaid Act (H.R.3990/ S.2071), disaster planning and readiness assistance for individuals with disabilities","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":56,"name":"Federal Emergency Management Agency (FEMA)"},{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/db9eadc1-42de-444d-85eb-7d9478453c88/","filing_uuid":"db9eadc1-42de-444d-85eb-7d9478453c88","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/db9eadc1-42de-444d-85eb-7d9478453c88/print/","filing_document_content_type":"text/html","income":null,"expenses":"75000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Maynard Friesz","dt_posted":"2026-04-01T21:02:59-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"50 Commerce Dr","registrant_address_2":"Suite 90","registrant_different_address":true,"registrant_city":"Schaumburg","registrant_state":"IL","registrant_zip":"60173","registrant":{"id":401104586,"url":"https://lda.gov/api/v1/registrants/401104586/","house_registrant_id":null,"name":"CURE SMA","description":"Non-profit","address_1":"50 Commerce Dr","address_2":"Suite 90","address_3":null,"address_4":null,"city":"Schaumburg","state":"IL","state_display":"Illinois","zip":"60173","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MAYNARD FRIESZ","contact_telephone":"+1 202-871-8004","dt_updated":"2026-07-10T12:05:55.658081-04:00"},"client":{"id":202103,"url":"https://lda.gov/api/v1/clients/202103/","client_id":12,"name":"CURE SMA","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"IL","state_display":"Illinois","country":"US","country_display":"United States of America","ppb_state":"IL","ppb_state_display":"Illinois","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-08-28"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Research into spinal muscular atrophy, timely access to care, treatments, medical devices, and home and community-based services, Give Kids a Chance Act (H.R.1261/ S.932- FDA Pediatric Priority Review Voucher Program), DOD Congressionally Directed Medical Research Program & Peer-Reviewed Medical Research Program, Labor-Health and Human Services, and Education Appropriations bill, Family Caregiver Awareness, Resources, and Education (CARE) Partnerships Act, Pediatric Palliative Care Homes, National Institute on Disability, Independent Living, and Rehabilitation Research funding, Seat Elevation in Group 2 Non-Complex Power Wheelchairs, Coverage of Standing Systems in Group 3 Power Wheelchair, Competitive Bidding for Tracheostomy, Ostomy and Urological Supplies; FDA Rare Disease Patient Listening Session, Coverage of Respiratory Assist Devices (RADs) and Home Mechanical Ventilators (HMVs), Accelerating Kids Access to Care Act (H.R. 1509/S. 752, National Institutes of Health funding; Medicaid home and community-based services, Public Law 119-21 Medicaid Community Engagement Requirements - disability and medically frail definition; Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343), Veterans STAND Act (H.R. 6835), Veterans SPORTS Act (S. 3138) Consolidated Appropriations Act of 2026 (P.L. 119-75)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"National Institutes of Health research into spinal muscular atrophy, U.S. Department of Defense Peer-Reviewed Medical Research in spinal muscular atrophy, Congressionally Directed Medical Research Program funding, Medicaid home and community-based services, housing (Sec. 811 Housing for People with Disabilities & Mainstream Housing Choice Vouchers), Defense Health Research Programs (Congressionally Directed Medical Research Programs), National Institute on Disability, Independent Living, and Rehabilitation Research funding, Labor-HHS-Education Appropriations bill, Transportation-HUD Appropriations bill, Defense Appropriations bill, Department of Education Office of Special Education and Rehabilitative Services staffing, Consolidated Appropriations Act of 2026 (P.L. 119-75), Assistive Technology Act program funding, Access Board funding","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":35,"name":"Housing & Urban Development, Dept of (HUD)"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":40,"name":"Transportation, Dept of (DOT)"}]},{"general_issue_code":"CIV","general_issue_code_display":"Civil Rights/Civil Liberties","description":"Supplemental Security Income Savings Penalty Elimination Act (H.R.2540/ S.1234), SSI Restoration Act, disability marriage penalty, Marriage Equality for Disabled Adults Act (H.R. 1389), Eliminating the Marriage Penalty in SSI Act (H.R. 320/ S.73), home and community-based services, Individuals with Disabilities Act (P.L. 101-336), ENABLE Act (H.R.1436/S.627), Seat Elevation in Group 2 Non-Complex Power Wheelchairs, Coverage of Standing Systems in Power Wheelchairs, Adult Changing Tables at U.S. Capitol, Department of Education Office of Special Education and Rehabilitative Services staffing and enforcement, Public Law 119-21 Implementation, including disability and medically frail definition for Medicaid Community Engagement Requirement; Veterans STAND Act (H.R. 6835), Veterans SPORTS Act (S. 3138), ABLE Tomorrow Act, the ABLE MATCH Act, and the ABLE Direct Deposit Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AVI","general_issue_code_display":"Aviation/Airlines/Airports","description":"FAA Reauthorization Act of 2024 (P.L. 118-63); Air Carrier Access Act (P.L. 99-435), Ensuring Safe Accommodations for Air Travelers with Disabilities Using Wheelchairs Final Rule, \"Ensuring Safe Accommodations for Air Travelers with Disabilities Using Wheelchairs Rule II, Transportation-HUD Appropriations bill, disability-related air travel complaints & aviation consumer protections","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":40,"name":"Transportation, Dept of (DOT)"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"U.S. Department of Defense Peer-Reviewed Medical Research Program Research in Spinal Muscular Atrophy, Funding for Defense Health Research Programs (Congressionally Directed Medical Research Programs and Peer Reviewed Medical Research Program), Medical Research for Our Troops Act (H.R. 3906)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HOU","general_issue_code_display":"Housing","description":"Transportation-HUD Appropriations bill, housing for people with disabilities (Sec. 811 Housing for People with Disabilities & Mainstream Housing Choice Vouchers), funding for disability and aging programs","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":35,"name":"Housing & Urban Development, Dept of (HUD)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"medical research in spinal muscular atrophy, development and approval of spinal muscular atrophy treatments, National Institutes of Health funding, U.S. Department of Defense peer reviewed research in spinal muscular atrophy, U.S. Department of Defense Congressionally Directed Medical Research Program funding, Medical Research for Our Troops Act (H.R. 3906)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicaid home and community-based services, Medicaid caregiving services, Medicaid funding, 2025 Budget Resolution, durable medical equipment, Pediatric Palliative Care Homes, H.R. 1, Think Differently Database Act (P.L. 118-225), Labor-HHS-Education Appropriations bill, Public Law 119-21 Implementation, including disability and medically frail definition for Medicaid Community Engagement Requirement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"ENABLE Act (H.R.1436/ S.627), Mobility Means Freedom Act (H.R.2320), Achieving a Better Life Experience (ABLE) Act (P.L. 113-295), H.R. 1, ABLE Tomorrow Act, the ABLE MATCH Act, and the ABLE Direct Deposit Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRA","general_issue_code_display":"Transportation","description":"FAA Reauthorization Act of 2024 (P.L. 118-63); Air Carrier Access Act (P.L. 99-435), Ensuring Safe Accommodations for Air Travelers with Disabilities Using Wheelchairs Final Rule, Disability Access to Transportation Act, accessibility in community transportation, Automated Vehicle (AV) Deployment and Research, Transportation-HUD Appropriations bill, surface transportation reauthorization","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":40,"name":"Transportation, Dept of (DOT)"}]},{"general_issue_code":"EDU","general_issue_code_display":"Education","description":"Labor, Health and Human Services, and Education Appropriations bill; IDEA Full Funding Act (H.R.2598/ S.1277), IDEA enforcement and oversight, Department of Education Office of Special Education and Rehabilitative Services staffing and enforcement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":32,"name":"Education, Dept of"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DIS","general_issue_code_display":"Disaster Planning/Emergencies","description":"Disaster Relief Medicaid Act (H.R.3990/ S.2071), disaster planning and readiness assistance for individuals with disabilities","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71876,"prefix":null,"prefix_display":null,"first_name":"MAYNARD","nickname":null,"middle_name":null,"last_name":"FRIESZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"BELLISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":56,"name":"Federal Emergency Management Agency (FEMA)"},{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/3c476b38-ce02-41d7-ac1b-0883140ce753/","filing_uuid":"3c476b38-ce02-41d7-ac1b-0883140ce753","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/3c476b38-ce02-41d7-ac1b-0883140ce753/print/","filing_document_content_type":"text/html","income":null,"expenses":"30000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Omar Noureldin","dt_posted":"2026-04-02T18:27:52-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"805 15TH STREET NW","registrant_address_2":"Suite 800","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":10150,"url":"https://lda.gov/api/v1/registrants/10150/","house_registrant_id":31882,"name":"COMMON CAUSE","description":"Nonprofit advocacy organization","address_1":"805 15TH STREET NW","address_2":"Suite 800","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"OMAR NOURELDIN","contact_telephone":"+1 202-386-8571","dt_updated":"2026-07-24T12:31:58.474144-04:00"},"client":{"id":114110,"url":"https://lda.gov/api/v1/clients/114110/","client_id":12,"name":"COMMON CAUSE","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2009-03-13"},"lobbying_activities":[{"general_issue_code":"GOV","general_issue_code_display":"Government Issues","description":"Voting & Elections Bills in the 119th Congress HR 14, John R. Lewis Voting Rights Advancement Act (Rep. Sewell, 216 cosponsors) HR 22, SAVE Act (Rep. Roy, 110 cosponsors)--passed the House 220-208 on April 10th HR 51, Washington, D.C. Admission Act (Rep. Norton, 191 cosponsors) HR 55, a bill to repeal the National Voter Registration Act (Rep. Biggs, 1 cosponsor) HR 58, Voter Integrity Protection Act (Rep. Biggs, 1 cosponsor) HR 126, Students Voicing Opinions in Todays Elections (VOTE) Act (Rep. Al Green, no cosponsors) HR 154, Election Day Act (Rep. Fitzpatrick, 1 cosponsor) HR 155, Let America Vote Act (Rep. Fitzpatrick, 3 cosponsors) HR 156, Securing Our Elections Act (Rep. Fitzpatrick, no cosponsors) HR 160, Restoring Faith in Elections Act (Rep. Fitzpatrick, no cosponsors) HR 529, Restoring American Confidence in Elections (RACE) Act (Rep. Pfluger, 1 cosponsor) HR 723, Protect American Election Administration Act (Rep. Cole, 9 cosponsors) HR 738, Universal Right to Vote by Mail Act (Rep. Salinas, 8 cosponsors) HR 882, No Foreign Persons Administering Our Elections Act (Rep. Pfluger, 9 cosponsors) HR 884, a bill to prohibit individuals who are not citizens of the United States from voting in elections in the District of Columbia and to repeal the Local Resident Voting Rights Amendment Act of 2022 (Rep. Pfluger, 10 cosponsors)--passed the House on June 10th HR 1467, POLE Act (Rep. Garbarino, no cosponsors) HR 2499, A bill to codify Executive Order 14248, entitled \"Preserving and Protecting the Integrity of American Elections\" (Rep. Hamadeh, 2 cosponsors) HR 2561, One Vote One Choice Act (Rep. Lawler, 2 cosponsors) HR 2562, District of Columbia One Vote One Choice Act (Rep. Lawler, 2 cosponsors) HR 2694, Election Results Accountability Act (Rep. Obernolte, 7 cosponsors) HR 2803, Protecting Election Administration from Interference Act (Rep. Veasey, 5 cosponsors) HR 2847, Vote At Home Act (Rep. Hoyle, 13 cosponsors) HR 2968, Business Over Ballots Act (Rep. Roger Williams, 12 cosponsors) HR 3040, Preventing Ranked Choice Corruption Act (Rep. Hamadeh, 1 cosponsor) S 51, Washington, D.C. Admission Act (Sen. Van Hollen, 43 cosponsors) S 128, SAVE Act (Sen. Lee, 28 cosponsors) S 1240, Defending America's Future Elections Act (Sen. Padilla, 12 cosponsors) S 1887, Vote at Home Act (Sen. Wyden, 12 cosponsors) S 2124, Election Worker Protection Act (Sen. Klobuchar, 16 cosponsors) Money in Politics Bills in the 119th Congress HR 415, Stop Act (Rep. Boyle, no cosponsors) HR 535, Inaugural Fund Transparency Act (Rep. Scanlon, 11 cosponsors) HR 1399, Prior Approval Reform Act (Rep. Amodei, no cosponsors) HR 2352, Abolish Super PACs Act (Rep. Summer Lee, 6 cosponsors) HR 2356, Dual Loyalty Disclosure Act (Rep. Massie, 3 cosponsors) HR 2476, Stop Illegal Campaign Coordination Act (Rep. Tokuda, 4 cosponsors) HR 2498, End Dark Money Act (Rep. Crow, 1 cosponsor) HR 2816, Shell Company Abuse Act (Rep. Bell, 3 cosponsors) HR 3311, Eliminating Leftover Expenses for Campaigns from Taxpayers (ELECT) Act (Rep. Steube, no cosponsors) HR 3535, Stop Foreign Funds in Elections Act (Rep. Fitzpatrick, 1 cosponsor) S 118, Inaugural Fund Transparency Act (Sen. Cortez Masto, 4 cosponsors) S 538, ELECT Act (Sen. Ernst, no cosponsors) S 1849, ZOMBIE Act (Sen. Bennet, no cosponsors) SJ Res 43, Democracy for All Amendment (Sen. Shaheen, 40 cosponsors) Redistricting/Census Bills in the 119th Congress HR 158, CLEAN Elections Act (Rep. Fitzpatrick, 1 cosponsor) HR 2797, House Expansion Commission Act (Rep. Stevens, 1 cosponsor) HR 3877, a bill to provide for the retrocession of the District of Columbia to Maryland (Rep. Griffith, no cosponsors) Ethics, Lobbying, and Other Government Reform Bills in the 119th Congress HR 253, Bipartisan Restoring Faith in Government Act (Rep. Fitzpatrick, 3 cosponsors) HR 358, No Corruption in Government Act (Rep. Nunn, 1 cosponsor) HR 396, TRUST in Congress Act (Rep. Magaziner, 76 cosponsors) HR 1074, Supreme Court Term Limits and Regular Appointments Act (Rep. Khanna, 8 cosponsors) HR 1712, Modern Emoluments and Malfeasance Enforcement (MEME) Act (Rep. Liccardo, 18 cosponsors) HR 1883, Lobbying Disclosure Improvement Act (Rep. Miller-Meeks, 1 cosponsor) HR 1887, Disclosing Foreign Influence in Lobbying Act (Rep. Neguse, 1 cosponsor) HR 1908, End Congressional Stock Trading Act (Rep. Burchett, 1 cosponsor) HR 2180, Keep the Watchdogs Running Act (Rep. Connolly, 10 cosponsors) HR 2181, Protect Our Watchdogs Act (Rep. Connolly, 25 cosponsors) HR 2361, Cameras in the Courtroom Act (Rep. Connolly, no cosponsors) HR 2593, MARALAGO Act (Rep. Cohen, no cosponsors) HR 2624, HUMBLE Act (Rep. Craig, 1 cosponsor) HR 2675, Protecting Our Courts from Foreign Manipulation Act (Rep. Cline, no cosponsors) HR 2737, ELON MUSK Act (Rep. Pocan, 14 cosponsors) HR 2857, Drain the Swamp Act (Rep. Khanna, 3 cosponsors) HR 2795, End Judge Shopping Act (Rep. Sherrill, no cosponsors) HR 3182, Transparency in Representation through Uniform Stock Trading Ban (TRUST) Act (Rep. Bresnahan, no cosponsors) HR 3229, Foreign Agents Transparency Act (Rep. Cline, 6 cosponsors) HR 3388, Preventing Elected Leaders from Owning Securities and Investments (Rep. Alford, 1 cosponsor) HR 3513, Supreme Court Ethics, Recusal, and Transparency Act (Rep. Hank Johnson, 32 cosponsors) HR 3544, Supreme Court Tenure Establishment and Retirement Modernization (TERM) Act (Rep. Hank Johnson, 47 cosponsors) HR 3554, Close the Revolving Door Act (Rep. Neguse, no cosponsors) HR 3573, Stop TRUMP in Crypto Act (Rep. Waters, 15 cosponsors) HR 3635, Foreign Adversary Investment Prohibition Act (Rep. Kean, 1 cosponsor) HR 3680, No Corporate Crooks Act (Rep. Deluzio, 5 cosponsors) HR 3776, Don't Settle for Bribes Act (Rep. Magaziner, 4 cosponsors) HR 3779, STOCK Act 2.0 (Rep. Dave Min, 9 cosponsors) HR 4036, No Shorting America Act (Rep. Kean, 1 cosponsor) S 588, Presidential Tax Transparency Act (Sen. Wyden, 8 cosponsors) S 806, Hatch Act Enforcement Transparency and Accountability Act (Sen. Lujan, 1 cosponsor) S 856, Disclosing Foreign Influence in Lobbying Act (Sen. Grassley, 5 cosponsors) S 865, Lobbying Disclosure Improvement Act (Sen. Peters, 1 cosponsor) S 981, Foreign Agents Transparency Act (Sen. Grassley, 3 cosponsors) S 1133, Sunshine in the Courtroom Act (Sen. Grassley, 5 cosponsors) S 1146, Cameras in the Courtroom Act (Sen. Durbin, 4 cosponsors) S 1196, Special Government Employees Transparency Act (Sen. Lujan, 7 cosponsors) S 1365, No Federal Payments to Companies Controlled by Special Government Employees Act (Sen. Shaheen, no cosponsors) S 1498, Preventing Elected Leaders from Owning Securities and Investments Act (Sen. Hawley, 1 cosponsor) S 1668, End Crypto Corruption Act (Sen. Merkley, 21 cosponsors) S 1803, STABLE GENIUS Act (Sen. Bennet, no cosponsors) S 1814, Supreme Court Ethics, Recusal, and Transparency Act (Sen. Whitehouse, 26 cosponsors) S 1850, Close the Revolving Door Act (Sen. Bennet, no cosponsors) S 1873, MARSHALS Act (Sen. Booker, 4 cosponsors) S 2132, a bill to amend title 18, United States Code, to prevent and mitigate the potential for conflicts of interest following government service (Sen. Cornyn, 3 cosponsors) --Voting & Fair Representation Bills in the 119th Congress-- - **HR 3776**, Don't Settle for Bribes Act of 2025 (Rep. Magaziner (RI-02), 1 cosponsor) - To restrict the President from initiating civil lawsuits regarding any civil matters arising during their presidency until after leaving office - **HR 4908**, Time Off to Vote Act (Rep. Williams (GA-05) / Hirono (HI), 52 cosponsors) - To provide employees with a minimum of 2 consecutive hours of paid leave in order to vote in Federal elections - **HR 4917**, Expanding the VOTE Act / Expanding the Voluntary Opportunities for Translations in Elections Act (Rep. Williams (GA-05), multiple cosponsors) - To modify certain notice requirements, reduce threshold requirements for language assistance under the Voting Rights Act, study certain election requirements, clarify certain election requirements - **HR 4910**, Sustaining Our Democracy Act (Rep. Williams (GA-05), multiple cosponsors) - To establish a democracy advancement and innovation program to promote innovation to improve efficiency and smooth functioning in the administration of elections for Federal office - **HR 4909**, Voters on the Move Registration Act of 2025 (Rep. Williams (GA-05), 45 cosponsors) - To protect voter registration for individuals who have changed residences and ensure portability of voter registration across jurisdictions - **HR 4914**, Unhoused Voter Opportunity Through Elections Act (Rep. Williams (GA-05), 48 cosponsors) - To ensure that unhoused individuals can exercise their right to vote by removing barriers related to permanent address requirements - **HR 4915**, Election Mail Act (Rep. Williams (GA-05), no cosponsors) - To address issues related to election mail and ensure timely delivery of ballots and election materials through the postal service - **HR 4911**, POLL Act / People Over Long Lines Act (Rep. Williams (GA-05), multiple cosponsors) - To amend the Help America Vote Act of 2002 to ensure that voters in elections for Federal office do not wait in long lines in order to vote, establish standards for wait times at polling locations - **HR 4916**, Youth Voting Rights Act (Rep. Williams (GA-05), 44 cosponsors) - To expand youth access to voting through pre-registration of minors, on-campus polling locations, prohibition of certain residency requirements, and private right of action for age discrimination in voting - **HR 4912**, Help America Run Act (Rep. Williams (GA-05), 41 cosponsors) - To support Americans running for elected office by providing resources, reducing barriers to candidacy, and promoting diverse representation in government - **HR 4913**, CHALLENGES Act / Countering Harassment and Applying Legal Liability to Effectively Nurture Government Election Stability Act (Rep. Williams (GA-05), 33 cosponsors) - To amend the National Voter Registration Act of 1993 to protect individuals who are lawfully registered to vote from bad faith challenges to their registration status, requires clear and convincing evidence for challenges, establishes penalties --Anti-Corruption & Accountability Bills in the 119th Congress-- - **HR 3454**, Protecting Our Constitution and Communities Act (Rep. Landsman (OH-01), 11 cosponsors) - To amend the Congressional Budget and Impoundment Control Act of 1974 to provide a private right of action with respect to violations of such Act, strengthen Government Accountability Office enforcement - **H.J.Res. 54** (118th Congress), We the People Amendment (Rep. Jayapal (WA-07), 216 cosponsors in 118th Congress, reintroduced in 119th) - Proposing an amendment to the Constitution of the United States providing that the rights protected and extended by the Constitution are the rights of natural persons only, ending corporate constitutional rights and reversing Citizens United - **HR 1118** (118th Congress), DISCLOSE Act / Democracy Is Strengthened by Casting Light On Spending in Elections Act (Rep. Cicilline/Pappas, multiple cosponsors) - To require disclosure of political spending and eliminate dark money in elections - **HR 5048** (118th Congress), Protecting Our Democracy Act (Rep. Schiff, 186 cosponsors) - Comprehensive reforms to prevent presidential abuses of power and restore checks and balances - **HR 5106** (119th Congress), Restore Trust in Congress Act (Rep. Roy (R-TX) + Rep. Magaziner (D-RI), bipartisan with approximately 100 cosponsors) - To ban congressional stock trading and address conflicts of interest - **S. 3191** (119th Congress), Stop Ballroom Bribery Act (Sen. Warren, cosponsors: Sen. Blumenthal, Sen. Markey lead, Sen. Booker, Sen. Hirono, Sen. Merkley) - To prevent corruption by prohibiting federal officials from soliciting or accepting donations for White House construction or improvements from private entities while in office - **HR 6085** (119th Congress), Stop Ballroom Bribery Act (Rep. Garcia, cosponsors: Reps Summer Lee, Ayanna Pressley, Pramila Jayapal) - House companion bill to prevent corruption involving Trump ballroom donations by prohibiting White House construction donations from private entities while president is in office H.R.6356 (119th Congress), Artificial Intelligence (AI) Civil Rights Act (Rep. Yvette Clarke) - To establish civil rights protections for algorithmic decision‑making systems by prohibiting discriminatory AI uses in key areas of life, requiring robust pre‑ and post‑deployment testing for bias, and increasing transparency and accountability for high‑risk AI tools. S. 5315 (117th Congress), Anti-Corruption and Public Integrity Act (Sen. Warren; Rep. Jayapal) - To overhaul federal ethics and anti‑corruption rules by locking the revolving door, ending lobbying as currently structured, restricting stock trading and corporate board service by senior officials, establishing an independent anti‑corruption agency, strengthening judicial ethics standards, and reforming campaign finance laws to curb the influence of big and dark money in politics. S. ____ ( )Financial Disclosure Modernization Act (Sen. Schiff) - To strengthen personal financial disclosure requirements for senior federal officials by modernizing and expanding reporting categories for large assets and income, improving electronic filing and public access, and enhancing transparency to help ensure that public officials act in the public interest rather than their own financial interests. S.4822 (117th Congress) DISCLOSE Act (Sen. Whitehouse) - To increase transparency in federal elections by requiring groups that spend significant sums on campaign‑related communications to disclose their major donors, thereby limiting the ability of dark money organizations to secretly influence federal elections and policymaking. H.R. 4213 / H.R. 7147 (119th Congress), Department of Homeland Security Appropriations Act, 2026 (House Appropriations Committee; House Republican leadership) - To provide full‑year fiscal year 2026 appropriations for the Department of Homeland Security, including border and immigration enforcement, disaster response, transportation security, and related programs, while incorporating policy riders and funding decisions that affect civil rights, immigration enforcement practices, and surveillance authorities. S.J.Res. 90 / H.Con.Res.64 (119th Congress), Venezuela War Powers Resolution (Sen. Kaine; Rep. McGovern) - To invoke the War Powers Resolution by directing the removal of United States Armed Forces from hostilities in or against Venezuela that have not been expressly authorized by Congress, thereby reasserting congressional authority over decisions to introduce U.S. forces into armed conflict. H.R. 7296 (119th Congress), SAVE America Act (Rep. Roy) - aims to ensure only U.S. citizens vote in federal elections. It mandates that states require documentary proof of U.S. citizenship for voter registration and imposes a photo ID requirement for voting in federal elections. H.Con.Res.38 - Directing the President pursuant to section 5(c) of the War Powers Resolution to remove United States Armed Forces from unauthorized hostilities in the Islamic Republic of Iran. (Rep. Massie). S.J.Res.104 - A joint resolution to direct the removal of United States Armed Forces from hostilities within or against the Islamic Republic of Iran that have not been authorized by Congress. (Sen. Tim Kaine). H.R.7147 - Further Additional Continuing Appropriations Act, 2026 (Rep. Tom Cole). H.R.7744 - Department of Homeland Security Appropriations Act, 2026 (Rep. Tom Cole).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145800,"prefix":null,"prefix_display":null,"first_name":"VIRGINIA","nickname":null,"middle_name":null,"last_name":"KASE SOLOMON","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":150350,"prefix":null,"prefix_display":null,"first_name":"OMAR","nickname":null,"middle_name":null,"last_name":"NOURELDIN","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153249,"prefix":null,"prefix_display":null,"first_name":"PRESTON","nickname":null,"middle_name":null,"last_name":"MITCHUM","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":217,"name":"Election Assistance Commission (EAC)"},{"id":53,"name":"Federal Communications Commission (FCC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":37,"name":"Justice, Dept of (DOJ)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Continuing resolution/government funding H.R.7147 - Further Additional Continuing Appropriations Act, 2026 (Rep. Tom Cole)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":150350,"prefix":null,"prefix_display":null,"first_name":"OMAR","nickname":null,"middle_name":null,"last_name":"NOURELDIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153249,"prefix":null,"prefix_display":null,"first_name":"PRESTON","nickname":null,"middle_name":null,"last_name":"MITCHUM","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":145800,"prefix":null,"prefix_display":null,"first_name":"VIRGINIA","nickname":null,"middle_name":null,"last_name":"KASE SOLOMON","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/1af2d18a-941f-47bc-86ea-01ddcd5e3910/","filing_uuid":"1af2d18a-941f-47bc-86ea-01ddcd5e3910","filing_type":"RR","filing_type_display":"Registration","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/1af2d18a-941f-47bc-86ea-01ddcd5e3910/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"HR Bert Pena, Esq.","dt_posted":"2026-04-06T10:39:26-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"4201 44th Street NW","registrant_address_2":null,"registrant_different_address":null,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20016","registrant":{"id":400323519,"url":"https://lda.gov/api/v1/registrants/400323519/","house_registrant_id":40271,"name":"MR. H.R. BERT PENA","description":"Law firm and consulting firm","address_1":"4201 44th Street NW","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20016","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"H.R. BERT PENA","contact_telephone":"+1 202-258-9485","dt_updated":"2026-09-25T18:25:38.682573-04:00"},"client":{"id":72214,"url":"https://lda.gov/api/v1/clients/72214/","client_id":72214,"name":"PHILLY PHARMACIES","general_description":"client is a pharmacy business in Philly","client_government_entity":null,"client_self_select":false,"state":"TX","state_display":"Texas","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-04-06"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"there are 2 pharmacies that serve in the Philadelphia area that are not approved by Optum to prescribe its products. thus, i am assisting the pharmacy group to obtain Optum's approval","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":59190,"prefix":null,"prefix_display":null,"first_name":"HR","nickname":null,"middle_name":"BERT","last_name":"PENA","suffix":null,"suffix_display":null},"covered_position":"former staff director of the House Committee on Agriculture","new":true}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/d8639a3a-108f-46da-955d-edb0191747d2/","filing_uuid":"d8639a3a-108f-46da-955d-edb0191747d2","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/d8639a3a-108f-46da-955d-edb0191747d2/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":"A","expenses_method_display":"A","posted_by_name":"Azeb Pickett","dt_posted":"2026-04-07T11:37:28-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"1828 L Street NW","registrant_address_2":"Suite 600","registrant_different_address":true,"registrant_city":"Washington D.C","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":11082,"url":"https://lda.gov/api/v1/registrants/11082/","house_registrant_id":33066,"name":"COUNCIL OF INSTITUTIONAL INVESTORS","description":null,"address_1":"1828 L Street NW","address_2":"Suite 600","address_3":null,"address_4":null,"city":"Washington D.C","state":"DC","state_display":"District of Columbia","zip":"20036","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AZEB PICKETT","contact_telephone":"+1 202-822-0800","dt_updated":"2026-07-09T10:04:40.709500-04:00"},"client":{"id":114922,"url":"https://lda.gov/api/v1/clients/114922/","client_id":12,"name":"COUNCIL OF INSTITUTIONAL INVESTORS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-07-30"},"lobbying_activities":[{"general_issue_code":"FIN","general_issue_code_display":"Financial Institutions/Investments/Securities","description":"Apr. 2, 2026CII letter to the SEC's Solicitation of Public Comment on Reforming Regulation S-K Jan. 13, 2026CII letter to SEC on Amendment to Nasdaq Proposed Rule Change, Attachment","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":49225,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY P","nickname":null,"middle_name":null,"last_name":"MAHONEY","suffix":null,"suffix_display":null},"covered_position":"General Counsel","new":false}],"government_entities":[{"id":88,"name":"Securities & Exchange Commission (SEC)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/ac880328-9812-45e7-b1a0-f459bfa6ad09/","filing_uuid":"ac880328-9812-45e7-b1a0-f459bfa6ad09","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/ac880328-9812-45e7-b1a0-f459bfa6ad09/print/","filing_document_content_type":"text/html","income":null,"expenses":"90000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Chris Dekker","dt_posted":"2026-04-07T14:27:29-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"26125 N. Riverwoods Blvd.","registrant_address_2":"Suite 500","registrant_different_address":false,"registrant_city":"Mettawa","registrant_state":"IL","registrant_zip":"60045","registrant":{"id":401109956,"url":"https://lda.gov/api/v1/registrants/401109956/","house_registrant_id":77227,"name":"BRUNSWICK CORPORATION","description":null,"address_1":"26125 N. Riverwoods Blvd.","address_2":"Suite 500","address_3":null,"address_4":null,"city":"Mettawa","state":"IL","state_display":"Illinois","zip":"60045","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHRIS DEKKER","contact_telephone":"+1 847-735-4251","dt_updated":"2026-07-13T20:24:38.987686-04:00"},"client":{"id":69026,"url":"https://lda.gov/api/v1/clients/69026/","client_id":69026,"name":"BRUNSWICK CORPORATION","general_description":"Manufacturer of recreational marine products, including boats, engines, electronics, parts","client_government_entity":null,"client_self_select":true,"state":"IL","state_display":"Illinois","country":"US","country_display":"United States of America","ppb_state":"IL","ppb_state_display":"Illinois","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-10-01"},"lobbying_activities":[{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to R&D tax credit, including those in P.L. 115-97 the Tax Cuts and Jobs Act (implementation and R&D treatments (Section 174)); issues to related tax deductibility of financing of marine products, including those in H.R.7222","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151487,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"JATIVA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues relating to international trade negotiations, including the USMCA Joint Review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151487,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"JATIVA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"MAN","general_issue_code_display":"Manufacturing","description":"Issues related to EPA's List 2 chemicals; issues related to Made in America procurement standards; issues related to the Fiscal Year 2026 Homeland Security Bill (Coast Guard appropriations provisions).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151487,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"JATIVA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":111,"name":"Natl Oceanic & Atmospheric Administration (NOAA)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MAR","general_issue_code_display":"Marine/Maritime/Boating/Fisheries","description":"Issues related to EPA's List 2 chemicals; issues related to Made in America procurement standards; issues related to the Fiscal Year 2026 Homeland Security Bill (Coast Guard appropriations provisions); issues to related tax deductibility of financing of marine products, including those in H.R.7222; issues related to marine related infrastructure spending, including S. 1547","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151487,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"JATIVA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":111,"name":"Natl Oceanic & Atmospheric Administration (NOAA)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/ac880328-9812-45e7-b1a0-f459bfa6ad09/","filing_uuid":"ac880328-9812-45e7-b1a0-f459bfa6ad09","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/ac880328-9812-45e7-b1a0-f459bfa6ad09/print/","filing_document_content_type":"text/html","income":null,"expenses":"90000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Chris Dekker","dt_posted":"2026-04-07T14:27:29-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"26125 N. Riverwoods Blvd.","registrant_address_2":"Suite 500","registrant_different_address":false,"registrant_city":"Mettawa","registrant_state":"IL","registrant_zip":"60045","registrant":{"id":401109956,"url":"https://lda.gov/api/v1/registrants/401109956/","house_registrant_id":77227,"name":"BRUNSWICK CORPORATION","description":null,"address_1":"26125 N. Riverwoods Blvd.","address_2":"Suite 500","address_3":null,"address_4":null,"city":"Mettawa","state":"IL","state_display":"Illinois","zip":"60045","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHRIS DEKKER","contact_telephone":"+1 847-735-4251","dt_updated":"2026-07-13T20:24:38.987686-04:00"},"client":{"id":69026,"url":"https://lda.gov/api/v1/clients/69026/","client_id":69026,"name":"BRUNSWICK CORPORATION","general_description":"Manufacturer of recreational marine products, including boats, engines, electronics, parts","client_government_entity":null,"client_self_select":true,"state":"IL","state_display":"Illinois","country":"US","country_display":"United States of America","ppb_state":"IL","ppb_state_display":"Illinois","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-10-01"},"lobbying_activities":[{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to R&D tax credit, including those in P.L. 115-97 the Tax Cuts and Jobs Act (implementation and R&D treatments (Section 174)); issues to related tax deductibility of financing of marine products, including those in H.R.7222","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151487,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"JATIVA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues relating to international trade negotiations, including the USMCA Joint Review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151487,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"JATIVA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"MAN","general_issue_code_display":"Manufacturing","description":"Issues related to EPA's List 2 chemicals; issues related to Made in America procurement standards; issues related to the Fiscal Year 2026 Homeland Security Bill (Coast Guard appropriations provisions).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151487,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"JATIVA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":111,"name":"Natl Oceanic & Atmospheric Administration (NOAA)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MAR","general_issue_code_display":"Marine/Maritime/Boating/Fisheries","description":"Issues related to EPA's List 2 chemicals; issues related to Made in America procurement standards; issues related to the Fiscal Year 2026 Homeland Security Bill (Coast Guard appropriations provisions); issues to related tax deductibility of financing of marine products, including those in H.R.7222; issues related to marine related infrastructure spending, including S. 1547","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151487,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"JATIVA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":111,"name":"Natl Oceanic & Atmospheric Administration (NOAA)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/8b24aee4-6580-4a2d-9518-e31c9ed74502/","filing_uuid":"8b24aee4-6580-4a2d-9518-e31c9ed74502","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/8b24aee4-6580-4a2d-9518-e31c9ed74502/print/","filing_document_content_type":"text/html","income":null,"expenses":"10000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Chava E. McKeel","dt_posted":"2026-04-07T15:58:04-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1421 RESEARCH PARK DRIVE","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"LAWRENCE","registrant_state":"KS","registrant_zip":"66049","registrant":{"id":16500,"url":"https://lda.gov/api/v1/registrants/16500/","house_registrant_id":32911,"name":"GOLF COURSE SUPERINTENDENTS ASSOCIATION OF AMERICA","description":"501(c)(6) professional society","address_1":"1421 RESEARCH PARK DRIVE","address_2":null,"address_3":null,"address_4":null,"city":"LAWRENCE","state":"KS","state_display":"Kansas","zip":"66049","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHAVA E. MCKEEL","contact_telephone":"+1 785-832-3619","dt_updated":"2026-07-16T12:44:08.159405-04:00"},"client":{"id":121840,"url":"https://lda.gov/api/v1/clients/121840/","client_id":12,"name":"GOLF COURSE SUPERINTENDENTS ASSOCIATION OF AMERICA","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"KS","state_display":"Kansas","country":"US","country_display":"United States of America","ppb_state":"KS","ppb_state_display":"Kansas","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2010-09-27"},"lobbying_activities":[{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"1. Re-write of \"Waters of the United States\" under the Clean Water Act. 2. S. 1907/H.R. 3783, the \"Plant Biostimulant Act of 2025\", which would create a uniform definition of plant biostimulants. 3. \"FIFRA 101\" meetings to discuss pesticide registration and regulation. 4. Turfgrass research funding under the Farm Bill. 5. Request meeting with Administrator of Environmental Protection Agency to discuss water and pesticide issues impacting golf industry.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65076,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"HELLAND","suffix":"jr","suffix_display":"JR"},"covered_position":null,"new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"1. H.R. 1583 the \"PAR Act\", which amends the Internal Revenue Code to remove private or commercial golf courses and country clubs from the list of uses from which certain proceeds cannot be used. 2. S. 4021/H.R. 7821, the \"Promoting Reduction of Emissions through Landscaping Equipment Act\", which provides a tax credit for businesses that either purchase zero-emission lawn, garden and landscape equipment or retrofit their existing gas-powered equipment.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65076,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"HELLAND","suffix":"jr","suffix_display":"JR"},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"ADV","general_issue_code_display":"Advertising","description":"Efforts to secure congressional sponsorship of resolution commemorating GCSAA's upcoming 100 year anniversary.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65076,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"HELLAND","suffix":"jr","suffix_display":"JR"},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"1. Efforts to secure additional H-2B Visas through appropriations and authorizing legislation. 2. Request to meet with Secretary of Labor to discuss H-2B Visas and workforce initiative issues impacting the golf industry.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65076,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"HELLAND","suffix":"jr","suffix_display":"JR"},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/8b24aee4-6580-4a2d-9518-e31c9ed74502/","filing_uuid":"8b24aee4-6580-4a2d-9518-e31c9ed74502","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/8b24aee4-6580-4a2d-9518-e31c9ed74502/print/","filing_document_content_type":"text/html","income":null,"expenses":"10000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Chava E. McKeel","dt_posted":"2026-04-07T15:58:04-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1421 RESEARCH PARK DRIVE","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"LAWRENCE","registrant_state":"KS","registrant_zip":"66049","registrant":{"id":16500,"url":"https://lda.gov/api/v1/registrants/16500/","house_registrant_id":32911,"name":"GOLF COURSE SUPERINTENDENTS ASSOCIATION OF AMERICA","description":"501(c)(6) professional society","address_1":"1421 RESEARCH PARK DRIVE","address_2":null,"address_3":null,"address_4":null,"city":"LAWRENCE","state":"KS","state_display":"Kansas","zip":"66049","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHAVA E. MCKEEL","contact_telephone":"+1 785-832-3619","dt_updated":"2026-07-16T12:44:08.159405-04:00"},"client":{"id":121840,"url":"https://lda.gov/api/v1/clients/121840/","client_id":12,"name":"GOLF COURSE SUPERINTENDENTS ASSOCIATION OF AMERICA","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"KS","state_display":"Kansas","country":"US","country_display":"United States of America","ppb_state":"KS","ppb_state_display":"Kansas","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2010-09-27"},"lobbying_activities":[{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"1. Re-write of \"Waters of the United States\" under the Clean Water Act. 2. S. 1907/H.R. 3783, the \"Plant Biostimulant Act of 2025\", which would create a uniform definition of plant biostimulants. 3. \"FIFRA 101\" meetings to discuss pesticide registration and regulation. 4. Turfgrass research funding under the Farm Bill. 5. Request meeting with Administrator of Environmental Protection Agency to discuss water and pesticide issues impacting golf industry.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65076,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"HELLAND","suffix":"jr","suffix_display":"JR"},"covered_position":null,"new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"1. H.R. 1583 the \"PAR Act\", which amends the Internal Revenue Code to remove private or commercial golf courses and country clubs from the list of uses from which certain proceeds cannot be used. 2. S. 4021/H.R. 7821, the \"Promoting Reduction of Emissions through Landscaping Equipment Act\", which provides a tax credit for businesses that either purchase zero-emission lawn, garden and landscape equipment or retrofit their existing gas-powered equipment.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65076,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"HELLAND","suffix":"jr","suffix_display":"JR"},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"ADV","general_issue_code_display":"Advertising","description":"Efforts to secure congressional sponsorship of resolution commemorating GCSAA's upcoming 100 year anniversary.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65076,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"HELLAND","suffix":"jr","suffix_display":"JR"},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"1. Efforts to secure additional H-2B Visas through appropriations and authorizing legislation. 2. Request to meet with Secretary of Labor to discuss H-2B Visas and workforce initiative issues impacting the golf industry.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65076,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"HELLAND","suffix":"jr","suffix_display":"JR"},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/6ad557c4-dd85-42a6-9b5e-52f37fe28068/","filing_uuid":"6ad557c4-dd85-42a6-9b5e-52f37fe28068","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/6ad557c4-dd85-42a6-9b5e-52f37fe28068/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":"A","expenses_method_display":"A","posted_by_name":"Andy Hale","dt_posted":"2026-04-13T12:24:08-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"134 S. 13 St., #800","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"LINCOLN","registrant_state":"NE","registrant_zip":"68508","registrant":{"id":55028,"url":"https://lda.gov/api/v1/registrants/55028/","house_registrant_id":35117,"name":"NEBRASKA HOSPITAL ASSOCIATION","description":null,"address_1":"3255 SALT CREEK CIRCLE, SUITE 100","address_2":null,"address_3":null,"address_4":null,"city":"LINCOLN","state":"NE","state_display":"Nebraska","zip":"68504","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ANDY HALE","contact_telephone":"+1 402-742-8146","dt_updated":"2026-07-13T12:52:35.804744-04:00"},"client":{"id":159203,"url":"https://lda.gov/api/v1/clients/159203/","client_id":12,"name":"NEBRASKA HOSPITAL ASSOCIATION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NE","state_display":"Nebraska","country":"US","country_display":"United States of America","ppb_state":"NE","ppb_state_display":"Nebraska","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-07-26"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Rural Health Transformation (RHT) Program One Big Beautiful Bill Act, (OBBBA) Medicare and Medicaid Programs: Minimum Staffing Standards for Long-Term Care Facilities and Medicaid Institutional Payment Transparency Reporting (CMS 3442-P) ARPA American Rescue Act Plan Funding OSHA Covid-19 Health Care Emergency Temporary Standard (ETS) Bill That Extends Moratorium on 2% Medicare Sequester Cuts Through End of 2021 Healthcare Price Transparency Rules for Hospitals 340B Medicare DSH Medicare Physician Payment (MACRA) H.R. 365 The Primary Care Enhancement Act S. 898/H.R. 2141 Conrad State 30 and Physician Access Reauthorization Act S. 1130 Rural Emergency Acute Care Hospital (REACH) Act S. 257 / H.R. 1611: Protecting Access to Rural Therapy Services Act S. 258 / H.R. 169: Critical Access Hospital Relief Act of 2015 H.R. 672 / S. 607: Rural Community Hospital Demonstration Extension Act of 2015 S. 1135: Hospital Payment Fairness Act H.R. 1479: Repeal of the Obamacare Bay State Boondoggle Act S. 1648: Rural Emergency Acute Care Hospital Act H.R. 3225: Save Rural Hospitals Act H.R. 1343 / S. 688: Establishing Beneficiary Equity in the Hospital Readmission Program Act S. 1148 / H.R. 2124: Resident Physician Shortage Reduction Act S. 2484 / H.R. 4442: CONNECT for Health Act H.R. 2156: Medicare Audit Improvement Act H.R. 5164: Rural Hospital Regulatory Relief Act S. 3435: Craig Thomas Rural Hospital and Provider Equity Act of 2016 H.R. 5406: Helping Ensure Accountability, Leadership, and Trust in Tribal Healthcare Act H.R. 34: 21st Century Cures Act H.R. 3298: Medicare Post-Acute Care Value-Based Purchasing Act H.R 1628: American Health Care Act S. 872 / H.R. 1955: Rural Hospital Access Act S. 377: Medicare Ambulance Access, Fraud Prevention and Reform Act H.R. 1156: Patient Access to Higher Quality Health Care Act of 2017 H.R. 2: Medicare Access and CHIP Reauthorization Act of 2016 H.R. 1628 Better Care Reconciliation Act (BCRA) H.R. 4392 To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes. The Senate Committee on Health, Education, Labor and Pensions (HELP) June 26 passed the Lower Health Care Costs Act of 2019 (S.1895) Congress should act now to delay the Medicaid DSH cuts that are scheduled to go into effect Nov. 22. The Coronavirus Aid, Relief, and Economic Security (CARES) Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67684,"prefix":null,"prefix_display":null,"first_name":"ANDY","nickname":null,"middle_name":"R","last_name":"HALE","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":148158,"prefix":null,"prefix_display":null,"first_name":"MEGHAN","nickname":null,"middle_name":null,"last_name":"CHAFFEE","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/9c34701c-f71d-4d65-81bc-130fe4e15d4b/","filing_uuid":"9c34701c-f71d-4d65-81bc-130fe4e15d4b","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/9c34701c-f71d-4d65-81bc-130fe4e15d4b/print/","filing_document_content_type":"text/html","income":null,"expenses":"350000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"David Cetola","dt_posted":"2026-04-13T14:19:58-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2564 US Highway 1","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Lawrence","registrant_state":"NJ","registrant_zip":"08648","registrant":{"id":400408933,"url":"https://lda.gov/api/v1/registrants/400408933/","house_registrant_id":null,"name":"SYENSQO USA LLC","description":"Solvay manufactures an extensive range of chemicals and plastics such as soda ash, etc.","address_1":"2564 US Highway 1","address_2":null,"address_3":null,"address_4":null,"city":"Lawrence","state":"NJ","state_display":"New Jersey","zip":"08648","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DAVE CETOLA","contact_telephone":"+1 609-819-5900","dt_updated":"2026-07-02T20:03:19.523398-04:00"},"client":{"id":190355,"url":"https://lda.gov/api/v1/clients/190355/","client_id":12,"name":"SYENSQO USA LLC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"TX","state_display":"Texas","country":"US","country_display":"United States of America","ppb_state":"TX","ppb_state_display":"Texas","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2009-03-17"},"lobbying_activities":[{"general_issue_code":"AER","general_issue_code_display":"Aerospace","description":"H.R. 3838, S. 2296, National Defense Authorization Act for Fiscal Year 2026, including provisions related to the procurement of aircraft. Potential bill for National Defense Authorization for Fiscal Year 2027, including provisions related to the procurement of aircraft, and appropriations for civil, space and defense aerospace platforms and associated materials in the aviation supply chain.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AUT","general_issue_code_display":"Automotive Industry","description":"Potential legislation that would incentivize recognizing advanced recycling and utilizing circular plastics in the automotive supply chain.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"AVI","general_issue_code_display":"Aviation/Airlines/Airports","description":"H.R. 3838, S. 2296, National Defense Authorization Act for Fiscal Year 2026, including provisions related to the procurement of aircraft. Technology export license governed by U.S. Department of Commerce Bureau of Industry and Security's Export Administration Regulations. Potential bill for National Defense Authorization for Fiscal Year 2027, including provisions related to the procurement of aircraft, and appropriations for civil, space and defense aerospace platforms and associated materials in the aviation supply chain.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":116,"name":"Defense Advanced Research Projects Agency (DARPA)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAR","general_issue_code_display":"Tariff (miscellaneous tariff bills)","description":"Potential House and Senate legislation related to the renewal of Miscellaneous Tariff Bill and Generalized System of Preferences.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"CHM","general_issue_code_display":"Chemicals/Chemical Industry","description":"H.R. 3838, S. 2296, National Defense Authorization Act for Fiscal Year 2026, including provisions related to the regulation of PFAS and CERCLA liability waivers. Potential bills for National Defense Authorization for Fiscal Year 2027, including provisions related to the regulation of PFAS and CERCLA liability waivers. Discussion Draft of Legislation to Modernize the Toxic Substances Control Act, including provisions related to updating EPA's TSCA review process. H.R. 1267, Water Systems PFAS Liability Protection Act, including provisions related to CERCLA exemptions for PFAS liability. H.R. 1415, S. 623, No IRIS Act, including provisions related to the use of assessments generated by the IRIS program. Potential Senate legislation directing EPA to regulate PFAS in certain sectors and environmental media, and exemptions to CERCLA liability. Potential Senate legislation to reform TSCA Section 5 requirements for significant new use notices. EPA's Advanced Notice of Proposed Rulemaking, Clean Water Act Effluent Limitations Guidelines and Standards for Organic Chemicals, Plastics and Synthetic Fibers Point Source Category. EPA's Rule on TSCA 8(a)(7) Reporting and Recordkeeping Requirements for PFAS Substances. EPA's New Chemical Review process under TSCA, including the process to approve new chemicals, low volume and polymer exemptions from TSCA's pre-manufacture notice requirements. EPA's final rule on National Primary Drinking Water Regulation for six PFAS, including PFOA, PFOS, PFNA, HFPO-DA, PFHxS and PFBS. EPA's final rule on designations of PFAS as CERCLA Hazardous Substances. EPA's proposed Toxic Substances Control Act risk management rule for Trichloroethylene (TCE), EPA-HQ-OPPT-2020-0642-0026, 88 Fed. Reg. 74,712 (Oct. 31, 2023). EPA's proposed rule on Procedures for Chemical Risk Evaluation under the Toxic Substances Control Act, EPA-HQ-OPPT-2023-0496, 88 Fed. Reg. 74,292 (Oct. 30, 2023). EPA's final revised risk determination for 1,4-dioxane under the Toxic Substances Control Act, EPA-HQ-OPPT-2016-0723, 89 Fed. Reg. 89,993 (Nov. 14, 2024). EPA's draft scope of the risk evaluation for vinyl chloride under the Toxic Substances Control Act, EPA-HQ-OPPT-2018-0448, 90 Fed. Reg. 4,738 (Jan. 16, 2025). EPA Pesticides Registration, Product code DV 5-26762 (Actizone), Reg. No. 4564-27.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"Department of Defense's Defense Production Act Title III program and Industrial Base Analysis and Sustainment (IBAS) program, including funding for projects that support national security. H.R. 3838, S. 2296, National Defense Authorization Act for Fiscal Year 2026, including provisions related to the support for the defense industrial base, reporting on uses of PFAS that are critical to national security. S. 4212, Prioritizing the Warfighter in Defense Contracting Act of 2026, including provisions related to prohibiting stock buybacks, dividends and caps compensation as a condition of contracting with the Department of Defense. Department of Defense Appropriations Act, 2027, including provisions related to national security projects under the Industrial Base Analysis and Sustainment (IBAS) program. Department of Defense Appropriations Act, 2026, including provisions related to national security projects under the Industrial Base Analysis and Sustainment (IBAS) program.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":116,"name":"Defense Advanced Research Projects Agency (DARPA)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"GOV","general_issue_code_display":"Government Issues","description":"Department of Justice's Advanced Notice of Proposed Rulemaking, Clarification and Modernization of Foreign Agents Registration Act (FARA) Implementing Regulations, including provisions related to the commercial exemption and the Lobbying Disclosure Act exemption. S. 4893, Lobbying Disclosure Improvement Act, including provisions related to LDA exemption disclosures.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"USTR's s. 301 investigation of China and associated tariff actions, including imports of vanillin flavoring products, semiconductor manufacturing chemicals and battery-grade fluoropolymers. USTR, Docket Nos. USTR-2026-03868 (91 FR 9686), Request for Comments on the Design of a Plurilateral Agreement on Trade in Critical Minerals and Policy Actions To Strengthen the Resilience of Critical Mineral Supply Chains. Docket Nos. USTR-2026-0067 (91 FR 13394), Initiation of Section 301 Investigations: Acts, Policies, and Practices of Certain Economies Relating to Structural Excess Capacity and Production in Manufacturing Sectors. USTR, Docket Nos. USTR-2026-0133 (91 FR 12884), Initiation of Section 301 Investigations of Acts, Policies, and Practices of Various Economies Related to the Failure to Impose and Effectively Enforce a Prohibition on the Importation of Goods Produced with Forced Labor. U.S. Department of Commerce and U.S. International Trade Commission investigation into unfairly priced imports of vanillin. USTR's Request for Comments to Assist in Reviewing and Identifying Unfair Trade Practices and Initiating All Necessary Actions to Investigate Harm From Non-Reciprocal Trade Arrangements, USTR-2025-0001. White House Executive Order 14154 Unleashing American Energy, including provisions related to the necessity of unleashing American energy and securing supply chains. White House Executive Order No. 14156 Declaring a National Energy Emergency, including provisions related to the immediate risk of the current precariously inadequate and intermittent energy supply, and an increasingly unreliable grid. Executive Order 14257 of April 2, 2025 (Regulating Imports With a Reciprocal Tariff to Rectify Trade Practices that Contribute to Large and Persistent Annual United States Goods Trade Deficits). Executive Order 14346 of September 5, 2025 (Modifying the Scope of Reciprocal Tariffs and Establishing Procedures for Implementing Trade and Security Agreements). Department of Commerce Request for Public Comments on Section 232 National Security Investigation of Imports of Semiconductors and Semiconductor Manufacturing Equipment, 90 FR 15950 (Apr. 16, 2025). US International Trade Commission Investigation, No. 337-TA-1439, battery-grade PVDF. Department of Commerce Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, 90 FR 15951 (Apr. 16, 2025). Department of Commerce Request for Public Comments on Section 232 National Security Investigation of Imports of Processed Critical Minerals and Derivative Products, 90 FR 17372 (Apr. 22, 2025). S. 3841, Last Sale Valuation Act of 2026, including provisions related to amending customs regulations concerning valuation of imports.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"RRR","general_issue_code_display":"Railroads","description":"Surface Transportation Board's Final Offer Rate Review (FORR).","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"ENG","general_issue_code_display":"Energy/Nuclear","description":"U.S. Department of Energy Qualifying Advanced Energy Project Credit (48C) Program. U.S. Department of Energy's Bipartisan Infrastructure Law Battery Materials Processing and Battery Manufacturing Funding Opportunity Announcement, DOE FOA-0002678 (May 2, 2022), including provisions related to the production of battery-grade materials.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":33,"name":"Energy, Dept of"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":39,"name":"State, Dept of (DOS)"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"EPA's Advanced Notice of Proposed Rulemaking, Clean Water Act Effluent Limitations Guidelines and Standards for Organic Chemicals, Plastics and Synthetic Fibers Point Source Category. EPA's final rule on National Primary Drinking Water Regulation for six PFAS, including PFOA, PFOS, PFNA, HFPO-DA, PFHxS and PFBS. UN Global Plastics Treaty negotiations, including provisions related to chemical management reform initiatives. H.R. 6566, Recycling Technology Innovation Act, including provisions related to amendments to Section 129 of the Clean Air Act and classification of advanced recycling.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"H.R. 842, Protecting the Right to Organize Act, including provisions related to state Right to Work laws and union dues.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"H.R. 1, One Big Beautiful Bill Act, including provisions related to clean energy tax credits and corporate tax modifications for US subsidiaries subject to foreign extraterritorial tax regimes. Department of Treasury's final regulations for the Section 30D New Clean Vehicle Credit (IRS-2023-0019) (Mar. 31, 2023), including provisions related to Critical Mineral and Battery Component Value Calculations, guidance on Foreign Entities of Concern prohibitions, and Department of Energy's final regulations on interpretation of Foreign Entity of Concern (DOE-2023-26513). Department of Treasury's final regulations for the Energy Security Tax Credits under Sections 48C and 45X (IRS-2022-0047) (Nov. 4, 2022), including provisions related to Critical Mineral and Battery Component Value Calculations, and guidance on Foreign Entities of Concern prohibitions. Department of Treasury, Internal Revenue Service's Guidance to Apply Interim Safe Harbors for Purposes of Determining a Taxpayers Material Assistance from a Prohibited Foreign Entity; Other Prohibited Foreign Entity Guidance (IRS Notice 2026-15). H.R. 591, Defending American Jobs and Investment Act, including provisions related to Undertaxed Profits Rule (UTPR), OECD Pillars I and II, and international tax provisions. H.R. 640, The Chemical Tax Repeal Act, including provisions related to repealing 2021 Superfund excise taxes.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"MAN","general_issue_code_display":"Manufacturing","description":"S. 4585, CHIPS EQUIP Act, including provisions related to prohibiting covered entities that receive federal assistance relating to semiconductors from purchasing certain equipment from FEOCs. H.R.7037, Developing Overseas Mineral Investments and New Allied Networks for Critical Energies (DOMINANCE) Act, including provisions related to directing diplomatic efforts with partners to coordinate mining, processing, manufacturing, environmental and labor standards, and supply commitments. H.R. 7126, Secure Minerals Act, including provisions related to establishing a critical mineral reserve and supporting domestic mining, processing, recycling and repurposing critical minerals.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HOM","general_issue_code_display":"Homeland Security","description":"Pub. L. 71-361, Tariff Act of 1930, including provisions related to the enforcement of forced labor regulations by Customs and Border Protection. H.R. 4470 and S. 2178, legislation to extend the Chemical Facility Anti-Terrorism Standards Program of the Department of Homeland Security, and for other purposes.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"MAR","general_issue_code_display":"Marine/Maritime/Boating/Fisheries","description":"IMO's proposal to classify plastic pellets as hazardous, including provisions related to UN shipping requirements, plastic pellets maritime spills and the maritime hazard classification process.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"FIN","general_issue_code_display":"Financial Institutions/Investments/Securities","description":"U.S. Securities and Exchange Commission Proposed Rule, \"The Enhancement and Standardization of Climate-Related Disclosures for Investors,\" including provisions related to corporate reporting of Scopes 1-3 emissions.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"Potential House legislation to support farmer education and adoption of tank adjuvants.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H. Con. Res 14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FOO","general_issue_code_display":"Food Industry (safety, labeling, etc.)","description":"S. 3122, Better FDA Act of 2025, including provisions related to modifications to FDA's oversight of the \"Generally Recognized as Safe\" framework. Make America Healthy Again Commission report, dated Sep. 9, 2025, under Executive Order 14212 titled \"Establishing the President's Make America Healthy Again Commission,\" including provisions related to guidance on water contaminants and the generally recognized as safe (GRAS) process. Proposed rule from the U.S. Food and Drug Administration on Substances Generally Recognized as Safe.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/9c34701c-f71d-4d65-81bc-130fe4e15d4b/","filing_uuid":"9c34701c-f71d-4d65-81bc-130fe4e15d4b","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/9c34701c-f71d-4d65-81bc-130fe4e15d4b/print/","filing_document_content_type":"text/html","income":null,"expenses":"350000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"David Cetola","dt_posted":"2026-04-13T14:19:58-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2564 US Highway 1","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Lawrence","registrant_state":"NJ","registrant_zip":"08648","registrant":{"id":400408933,"url":"https://lda.gov/api/v1/registrants/400408933/","house_registrant_id":null,"name":"SYENSQO USA LLC","description":"Solvay manufactures an extensive range of chemicals and plastics such as soda ash, etc.","address_1":"2564 US Highway 1","address_2":null,"address_3":null,"address_4":null,"city":"Lawrence","state":"NJ","state_display":"New Jersey","zip":"08648","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DAVE CETOLA","contact_telephone":"+1 609-819-5900","dt_updated":"2026-07-02T20:03:19.523398-04:00"},"client":{"id":190355,"url":"https://lda.gov/api/v1/clients/190355/","client_id":12,"name":"SYENSQO USA LLC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"TX","state_display":"Texas","country":"US","country_display":"United States of America","ppb_state":"TX","ppb_state_display":"Texas","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2009-03-17"},"lobbying_activities":[{"general_issue_code":"AER","general_issue_code_display":"Aerospace","description":"H.R. 3838, S. 2296, National Defense Authorization Act for Fiscal Year 2026, including provisions related to the procurement of aircraft. Potential bill for National Defense Authorization for Fiscal Year 2027, including provisions related to the procurement of aircraft, and appropriations for civil, space and defense aerospace platforms and associated materials in the aviation supply chain.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AUT","general_issue_code_display":"Automotive Industry","description":"Potential legislation that would incentivize recognizing advanced recycling and utilizing circular plastics in the automotive supply chain.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"AVI","general_issue_code_display":"Aviation/Airlines/Airports","description":"H.R. 3838, S. 2296, National Defense Authorization Act for Fiscal Year 2026, including provisions related to the procurement of aircraft. Technology export license governed by U.S. Department of Commerce Bureau of Industry and Security's Export Administration Regulations. Potential bill for National Defense Authorization for Fiscal Year 2027, including provisions related to the procurement of aircraft, and appropriations for civil, space and defense aerospace platforms and associated materials in the aviation supply chain.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":116,"name":"Defense Advanced Research Projects Agency (DARPA)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAR","general_issue_code_display":"Tariff (miscellaneous tariff bills)","description":"Potential House and Senate legislation related to the renewal of Miscellaneous Tariff Bill and Generalized System of Preferences.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"CHM","general_issue_code_display":"Chemicals/Chemical Industry","description":"H.R. 3838, S. 2296, National Defense Authorization Act for Fiscal Year 2026, including provisions related to the regulation of PFAS and CERCLA liability waivers. Potential bills for National Defense Authorization for Fiscal Year 2027, including provisions related to the regulation of PFAS and CERCLA liability waivers. Discussion Draft of Legislation to Modernize the Toxic Substances Control Act, including provisions related to updating EPA's TSCA review process. H.R. 1267, Water Systems PFAS Liability Protection Act, including provisions related to CERCLA exemptions for PFAS liability. H.R. 1415, S. 623, No IRIS Act, including provisions related to the use of assessments generated by the IRIS program. Potential Senate legislation directing EPA to regulate PFAS in certain sectors and environmental media, and exemptions to CERCLA liability. Potential Senate legislation to reform TSCA Section 5 requirements for significant new use notices. EPA's Advanced Notice of Proposed Rulemaking, Clean Water Act Effluent Limitations Guidelines and Standards for Organic Chemicals, Plastics and Synthetic Fibers Point Source Category. EPA's Rule on TSCA 8(a)(7) Reporting and Recordkeeping Requirements for PFAS Substances. EPA's New Chemical Review process under TSCA, including the process to approve new chemicals, low volume and polymer exemptions from TSCA's pre-manufacture notice requirements. EPA's final rule on National Primary Drinking Water Regulation for six PFAS, including PFOA, PFOS, PFNA, HFPO-DA, PFHxS and PFBS. EPA's final rule on designations of PFAS as CERCLA Hazardous Substances. EPA's proposed Toxic Substances Control Act risk management rule for Trichloroethylene (TCE), EPA-HQ-OPPT-2020-0642-0026, 88 Fed. Reg. 74,712 (Oct. 31, 2023). EPA's proposed rule on Procedures for Chemical Risk Evaluation under the Toxic Substances Control Act, EPA-HQ-OPPT-2023-0496, 88 Fed. Reg. 74,292 (Oct. 30, 2023). EPA's final revised risk determination for 1,4-dioxane under the Toxic Substances Control Act, EPA-HQ-OPPT-2016-0723, 89 Fed. Reg. 89,993 (Nov. 14, 2024). EPA's draft scope of the risk evaluation for vinyl chloride under the Toxic Substances Control Act, EPA-HQ-OPPT-2018-0448, 90 Fed. Reg. 4,738 (Jan. 16, 2025). EPA Pesticides Registration, Product code DV 5-26762 (Actizone), Reg. No. 4564-27.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"Department of Defense's Defense Production Act Title III program and Industrial Base Analysis and Sustainment (IBAS) program, including funding for projects that support national security. H.R. 3838, S. 2296, National Defense Authorization Act for Fiscal Year 2026, including provisions related to the support for the defense industrial base, reporting on uses of PFAS that are critical to national security. S. 4212, Prioritizing the Warfighter in Defense Contracting Act of 2026, including provisions related to prohibiting stock buybacks, dividends and caps compensation as a condition of contracting with the Department of Defense. Department of Defense Appropriations Act, 2027, including provisions related to national security projects under the Industrial Base Analysis and Sustainment (IBAS) program. Department of Defense Appropriations Act, 2026, including provisions related to national security projects under the Industrial Base Analysis and Sustainment (IBAS) program.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":116,"name":"Defense Advanced Research Projects Agency (DARPA)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"GOV","general_issue_code_display":"Government Issues","description":"Department of Justice's Advanced Notice of Proposed Rulemaking, Clarification and Modernization of Foreign Agents Registration Act (FARA) Implementing Regulations, including provisions related to the commercial exemption and the Lobbying Disclosure Act exemption. S. 4893, Lobbying Disclosure Improvement Act, including provisions related to LDA exemption disclosures.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"USTR's s. 301 investigation of China and associated tariff actions, including imports of vanillin flavoring products, semiconductor manufacturing chemicals and battery-grade fluoropolymers. USTR, Docket Nos. USTR-2026-03868 (91 FR 9686), Request for Comments on the Design of a Plurilateral Agreement on Trade in Critical Minerals and Policy Actions To Strengthen the Resilience of Critical Mineral Supply Chains. Docket Nos. USTR-2026-0067 (91 FR 13394), Initiation of Section 301 Investigations: Acts, Policies, and Practices of Certain Economies Relating to Structural Excess Capacity and Production in Manufacturing Sectors. USTR, Docket Nos. USTR-2026-0133 (91 FR 12884), Initiation of Section 301 Investigations of Acts, Policies, and Practices of Various Economies Related to the Failure to Impose and Effectively Enforce a Prohibition on the Importation of Goods Produced with Forced Labor. U.S. Department of Commerce and U.S. International Trade Commission investigation into unfairly priced imports of vanillin. USTR's Request for Comments to Assist in Reviewing and Identifying Unfair Trade Practices and Initiating All Necessary Actions to Investigate Harm From Non-Reciprocal Trade Arrangements, USTR-2025-0001. White House Executive Order 14154 Unleashing American Energy, including provisions related to the necessity of unleashing American energy and securing supply chains. White House Executive Order No. 14156 Declaring a National Energy Emergency, including provisions related to the immediate risk of the current precariously inadequate and intermittent energy supply, and an increasingly unreliable grid. Executive Order 14257 of April 2, 2025 (Regulating Imports With a Reciprocal Tariff to Rectify Trade Practices that Contribute to Large and Persistent Annual United States Goods Trade Deficits). Executive Order 14346 of September 5, 2025 (Modifying the Scope of Reciprocal Tariffs and Establishing Procedures for Implementing Trade and Security Agreements). Department of Commerce Request for Public Comments on Section 232 National Security Investigation of Imports of Semiconductors and Semiconductor Manufacturing Equipment, 90 FR 15950 (Apr. 16, 2025). US International Trade Commission Investigation, No. 337-TA-1439, battery-grade PVDF. Department of Commerce Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, 90 FR 15951 (Apr. 16, 2025). Department of Commerce Request for Public Comments on Section 232 National Security Investigation of Imports of Processed Critical Minerals and Derivative Products, 90 FR 17372 (Apr. 22, 2025). S. 3841, Last Sale Valuation Act of 2026, including provisions related to amending customs regulations concerning valuation of imports.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"RRR","general_issue_code_display":"Railroads","description":"Surface Transportation Board's Final Offer Rate Review (FORR).","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"ENG","general_issue_code_display":"Energy/Nuclear","description":"U.S. Department of Energy Qualifying Advanced Energy Project Credit (48C) Program. U.S. Department of Energy's Bipartisan Infrastructure Law Battery Materials Processing and Battery Manufacturing Funding Opportunity Announcement, DOE FOA-0002678 (May 2, 2022), including provisions related to the production of battery-grade materials.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":33,"name":"Energy, Dept of"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":39,"name":"State, Dept of (DOS)"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"EPA's Advanced Notice of Proposed Rulemaking, Clean Water Act Effluent Limitations Guidelines and Standards for Organic Chemicals, Plastics and Synthetic Fibers Point Source Category. EPA's final rule on National Primary Drinking Water Regulation for six PFAS, including PFOA, PFOS, PFNA, HFPO-DA, PFHxS and PFBS. UN Global Plastics Treaty negotiations, including provisions related to chemical management reform initiatives. H.R. 6566, Recycling Technology Innovation Act, including provisions related to amendments to Section 129 of the Clean Air Act and classification of advanced recycling.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"H.R. 842, Protecting the Right to Organize Act, including provisions related to state Right to Work laws and union dues.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"H.R. 1, One Big Beautiful Bill Act, including provisions related to clean energy tax credits and corporate tax modifications for US subsidiaries subject to foreign extraterritorial tax regimes. Department of Treasury's final regulations for the Section 30D New Clean Vehicle Credit (IRS-2023-0019) (Mar. 31, 2023), including provisions related to Critical Mineral and Battery Component Value Calculations, guidance on Foreign Entities of Concern prohibitions, and Department of Energy's final regulations on interpretation of Foreign Entity of Concern (DOE-2023-26513). Department of Treasury's final regulations for the Energy Security Tax Credits under Sections 48C and 45X (IRS-2022-0047) (Nov. 4, 2022), including provisions related to Critical Mineral and Battery Component Value Calculations, and guidance on Foreign Entities of Concern prohibitions. Department of Treasury, Internal Revenue Service's Guidance to Apply Interim Safe Harbors for Purposes of Determining a Taxpayers Material Assistance from a Prohibited Foreign Entity; Other Prohibited Foreign Entity Guidance (IRS Notice 2026-15). H.R. 591, Defending American Jobs and Investment Act, including provisions related to Undertaxed Profits Rule (UTPR), OECD Pillars I and II, and international tax provisions. H.R. 640, The Chemical Tax Repeal Act, including provisions related to repealing 2021 Superfund excise taxes.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"MAN","general_issue_code_display":"Manufacturing","description":"S. 4585, CHIPS EQUIP Act, including provisions related to prohibiting covered entities that receive federal assistance relating to semiconductors from purchasing certain equipment from FEOCs. H.R.7037, Developing Overseas Mineral Investments and New Allied Networks for Critical Energies (DOMINANCE) Act, including provisions related to directing diplomatic efforts with partners to coordinate mining, processing, manufacturing, environmental and labor standards, and supply commitments. H.R. 7126, Secure Minerals Act, including provisions related to establishing a critical mineral reserve and supporting domestic mining, processing, recycling and repurposing critical minerals.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HOM","general_issue_code_display":"Homeland Security","description":"Pub. L. 71-361, Tariff Act of 1930, including provisions related to the enforcement of forced labor regulations by Customs and Border Protection. H.R. 4470 and S. 2178, legislation to extend the Chemical Facility Anti-Terrorism Standards Program of the Department of Homeland Security, and for other purposes.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"MAR","general_issue_code_display":"Marine/Maritime/Boating/Fisheries","description":"IMO's proposal to classify plastic pellets as hazardous, including provisions related to UN shipping requirements, plastic pellets maritime spills and the maritime hazard classification process.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"FIN","general_issue_code_display":"Financial Institutions/Investments/Securities","description":"U.S. Securities and Exchange Commission Proposed Rule, \"The Enhancement and Standardization of Climate-Related Disclosures for Investors,\" including provisions related to corporate reporting of Scopes 1-3 emissions.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"Potential House legislation to support farmer education and adoption of tank adjuvants.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H. Con. Res 14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FOO","general_issue_code_display":"Food Industry (safety, labeling, etc.)","description":"S. 3122, Better FDA Act of 2025, including provisions related to modifications to FDA's oversight of the \"Generally Recognized as Safe\" framework. Make America Healthy Again Commission report, dated Sep. 9, 2025, under Executive Order 14212 titled \"Establishing the President's Make America Healthy Again Commission,\" including provisions related to guidance on water contaminants and the generally recognized as safe (GRAS) process. Proposed rule from the U.S. Food and Drug Administration on Substances Generally Recognized as Safe.","foreign_entity_issues":"As parent entities of Syensqo USA LLC, Syensqo SA and Syensqo France SA have a generalized interest in the issues above.","lobbyists":[{"lobbyist":{"id":80986,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"CETOLA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147477,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"KA CHUN","last_name":"LAI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147511,"prefix":null,"prefix_display":null,"first_name":"IAN","nickname":null,"middle_name":null,"last_name":"CHOINIERE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/58e9affa-7523-41be-84db-5d6cc16d033e/","filing_uuid":"58e9affa-7523-41be-84db-5d6cc16d033e","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/58e9affa-7523-41be-84db-5d6cc16d033e/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Matt McGinley","dt_posted":"2026-04-14T09:45:45-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2503-D Harrison Street North #1210","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Arlington","registrant_state":"VA","registrant_zip":"22207","registrant":{"id":401103524,"url":"https://lda.gov/api/v1/registrants/401103524/","house_registrant_id":null,"name":"ADVANCED POLICY CONSULTING, LLC","description":"Consulting","address_1":"2503-D Harrison Street North #1210","address_2":null,"address_3":null,"address_4":null,"city":"Arlington","state":"VA","state_display":"Virginia","zip":"22207","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MATT MCGINLEY","contact_telephone":"+1 703-536-1705","dt_updated":"2026-07-24T11:29:57.639066-04:00"},"client":{"id":199378,"url":"https://lda.gov/api/v1/clients/199378/","client_id":90,"name":"MANUFACTURED HOUSING INSTITUTE (MHI)","general_description":"Trade association","client_government_entity":false,"client_self_select":null,"state":"VA","state_display":"Virginia","country":"US","country_display":"United States of America","ppb_state":"VA","ppb_state_display":"Virginia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2015-08-06"},"lobbying_activities":[{"general_issue_code":"HOU","general_issue_code_display":"Housing","description":"Monitor manufactured housing issues. Lobby against a Department of Energy proposal that uses the 2021 International Energy Conservation Code. Regulation proposal EERE-2009-BT-BC-0021-0592. The law requires the DOE to establish energy standards for manufactured housing based on the most recent version of the IECC unless using such a code is found not to be cost effective. The DOE's proposal is not cost effective as drafted and would increase the price of manufactured housing. Place language in the Energy and Water (E&W) Appropriations and Transportation, Housing and Urban Development (THUD) Appropriations legislation to fix the DOE regulation so it is workable. Same regarding any Senate appropriations legislation. Support changes to appropriation bills to ensure that HUD would be the primary regulator over DOE regulations that would impact the HUD housing code for manufactured housing. HUD should update FHA's guidelines to ensure Title I and Title II programs support manufactured housing. Support federal efforts to preserve and develop manufactured housing communities to include all eligible homeownership types. Affordable HOMES Act HR 5184","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":62356,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"MCGINLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":33,"name":"Energy, Dept of"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":35,"name":"Housing & Urban Development, Dept of (HUD)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Monitor tax issues as they relate to manufactured housing. Support Section 45L Energy Efficient Home Credit.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":62356,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"MCGINLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BNK","general_issue_code_display":"Bankruptcy","description":"Congress took a critical step in 2005 to include home-only loans in the definition of a principal residence- but without aligning 1322(b)(2), the protection remains incomplete. Congress should enact a clarifying amendment to extend 1322(b)(2)s protection to all loans secured by a debtors primary residence, as it intended with the 2005 amendment. This would prevent cram downs on manufactured home-only loans, which constitute nearly two-thirds of all loans in the manufactured housing market. By aligning treatment with site-built home mortgages, the bankruptcy code will help preserve lending in this vital affordable housing sector.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":62356,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"MCGINLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/808d8e28-5cf8-4819-91b8-da7f7e3cc070/","filing_uuid":"808d8e28-5cf8-4819-91b8-da7f7e3cc070","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/808d8e28-5cf8-4819-91b8-da7f7e3cc070/print/","filing_document_content_type":"text/html","income":null,"expenses":"683996.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"David R Tully","dt_posted":"2026-04-14T11:03:55-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 TOMAHAWK CREEK PARKWAY","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"LEAWOOD","registrant_state":"KS","registrant_zip":"66211","registrant":{"id":1342,"url":"https://lda.gov/api/v1/registrants/1342/","house_registrant_id":32180,"name":"AMERICAN ACADEMY OF FAMILY PHYSICIANS","description":null,"address_1":"11400 TOMAHAWK CREEK PARKWAY","address_2":null,"address_3":null,"address_4":null,"city":"LEAWOOD","state":"KS","state_display":"Kansas","zip":"66211","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DAVID TULLY","contact_telephone":"+1 202-232-9033","dt_updated":"2026-07-22T14:55:32.986947-04:00"},"client":{"id":102605,"url":"https://lda.gov/api/v1/clients/102605/","client_id":12,"name":"AMERICAN ACADEMY OF FAMILY PHYSICIANS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"KS","state_display":"Kansas","country":"US","country_display":"United States of America","ppb_state":"KS","ppb_state_display":"Kansas","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-02"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"No Bill No. - FY26 Appropriations No Bill No. - FY27 Appropriations","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":72463,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":83708,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"TULLY","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant - Rep. Kay Granger (R-Tx)","new":false},{"lobbyist":{"id":142935,"prefix":"ms","prefix_display":"MS.","first_name":"NATALIE","nickname":null,"middle_name":"ELAINE","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":145174,"prefix":"ms","prefix_display":"MS.","first_name":"ANNA","nickname":null,"middle_name":"SCHAUT","last_name":"WALDMAN","suffix":null,"suffix_display":null},"covered_position":"Intern - Senator Kirsten Gillibrand (D-NY)","new":true},{"lobbyist":{"id":146729,"prefix":null,"prefix_display":null,"first_name":"MEGAN","nickname":null,"middle_name":null,"last_name":"MORTIMER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":149012,"prefix":"ms","prefix_display":"MS.","first_name":"KATE","nickname":null,"middle_name":"WALLIS","last_name":"GILLIARD","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"EDU","general_issue_code_display":"Education","description":"No Bill No. - Graduate Medical Education Reform No Bill No. - Resident Education Deferred Interest (REDI) Act No Bill No. - Public Service Loan Forgiveness Program No Bill No. - EDUCATE Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":72463,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":83708,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"TULLY","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant - Rep. Kay Granger (R-Tx)","new":false},{"lobbyist":{"id":142935,"prefix":"ms","prefix_display":"MS.","first_name":"NATALIE","nickname":null,"middle_name":"ELAINE","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":145174,"prefix":"ms","prefix_display":"MS.","first_name":"ANNA","nickname":null,"middle_name":"SCHAUT","last_name":"WALDMAN","suffix":null,"suffix_display":null},"covered_position":"Intern, Sen. Kirsten Gillibrand (D-NY)","new":true},{"lobbyist":{"id":146729,"prefix":null,"prefix_display":null,"first_name":"MEGAN","nickname":null,"middle_name":null,"last_name":"MORTIMER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":149012,"prefix":"ms","prefix_display":"MS.","first_name":"KATE","nickname":null,"middle_name":"WALLIS","last_name":"GILLIARD","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"No Bill No. - Reducing Medically Unnecessary Delays in Care Act No Bill No. - Global Health Empowerment and Rights (Global HER) Act No Bill No. - WHO withdrawal No Bill No. - Chronic Disease Flexible Coverage Act No Bill No. - Rural Physician Workforce Production Act No Bill No. - Bringing Low-Cost Options and Competition While Keeping Incentives for New Generics (BLOCKING) Act No Bill No. - Protecting Patients from Deceptive Drug Ads Online Act No Bill No. - Protect Health Savings Account Act No Bill No. - HHS reorganization No Bill No. - Workforce Mobility Act No Bill No. - Health Care Workforce Expansion Act No Bill No. - TRUTH in Labeling Act No Bill No. - NIH Clinical Trial Integrity Act (H.R. 21/S.6) - Born-Alive Abortion Survivors Protection Act (H.R. 1061) - Protecting Sensitive Locations Act (S. 229) - Drug Price Transparency for Consumers (DTC) Act (H.R. 777) - Closing the College Hunger Gap Act (H.R. 957) - Parity Enforcement Act (H.R. 846/S.589) - Stop Anti-Abortion Disinformation (SAD) Act (H.R. 929/S.266) - Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 1670/S. 797) - Family Building FEHB Fairness Act (S. 1538) - Rural Seniors Act (H.R. 999/S. 422) - Right to Contraception Act (H.R. 2818/S. 1447) - Early Childhood Nutrition Improvement Act (H.R. 2559/S. 1420) - Child Care Nutrition Enhancement Act (H.R. 2495/S. 1971) - Nutrition Counseling Aiding Recovery for Eating Disorders (CARE) Act (H.R. 2483) - SUPPORT for Patients and Communities Reauthorization Act (H.R. 2762/S. 1394) - Expanding Access to Family Planning Act (H.R. 2717/S. 1320) - Servicewoman and Veterans Menopause Research Act (H.R. 1) - One Big Beautiful Bill Act (H.R. 1026/s. 1719) - Improving Seniors' Timely Access to Care Act (H.R. 3757) - Supporting Healthy Mothers and Infants Act (S. 5469) - SHINE for Autumn Act (S. 1562/H.R. 1197) - PREEMIE Reauthorization Act (H.R. 3670) - IHS Provider Expansion Act (S. 2072) - MORE Savings Act (S. 2169) - Rural Hospital Cybersecurity Act (S. 1847/H.R. 3672) - Supporting Healthy Moms and Babies Act (H.R. 3885) - TEAMS Act (H.R. 3942) - Keeping Obstetrics Local Act (H.R. 4837) - Written Informed Consent Act (H.R. 3013) - Vaccine Transportation Act (H.R. 6468) - Rural Residency Planning and Development Act of 2025 (H.R. 6760) - Protecting Access to Affordable Coverage Act (H.R. 5461/S.2211) - Special Diabetes Program Reauthorization Act (H.R. 5684) - Medical Foods and Formulas Access Act (H.R. 7064) - AI in Healthcare Efficiency and Study Act (S. 4027/H.R. 6248) - Healthy Competition for Better Care Act (S. 3842) - 21st Century WIC Act (H.R. 5488) - Special Diabetes Program for Indians Reauthorization Act (S. 3274/H.R. 6242) - Healthy Maternity and Obstetric Medicine (MOM) Act (H.R. 5360) - AI Warnings and Resources for Education (AWARE) Act (H.R. 6353) - Algorithmic Choice and Transparency Act (H.R. 6292) - Don't Sell Kid's Data Act (S. 3618/H.R. 6259) - No Fentanyl on Social Media Act (H.R. 6498) - Safeguarding Adolescents from Exploitative (SAFE) Bots Act (H.R. 6290) - Safe Social Media Act (H.R. 7227/S.3698) - Mental Health and Making Access More Affordable (MAMA) Act (H.R. 7444) - Protecting Rural Telehealth Access Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":72463,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":83708,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"TULLY","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant - Rep. Kay Granger (R-Tx)","new":false},{"lobbyist":{"id":142935,"prefix":"ms","prefix_display":"MS.","first_name":"NATALIE","nickname":null,"middle_name":"ELAINE","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145174,"prefix":"ms","prefix_display":"MS.","first_name":"ANNA","nickname":null,"middle_name":"SCHAUT","last_name":"WALDMAN","suffix":null,"suffix_display":null},"covered_position":"Intern - Sen. Kirsten Gillibrand (D-NY)","new":true},{"lobbyist":{"id":146729,"prefix":null,"prefix_display":null,"first_name":"MEGAN","nickname":null,"middle_name":null,"last_name":"MORTIMER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":149012,"prefix":"ms","prefix_display":"MS.","first_name":"KATE","nickname":null,"middle_name":"WALLIS","last_name":"GILLIARD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"No Bill No. - Physician payment reform No Bill No. - Value based care No Bill No. - Kids Access to Primary Care Act No Bill No. - Medicaid Primary Care Improvement Act No Bill No. - Alleviating Barriers for Caregivers (ABC) Act No Bill No. - MA Prompt Pay (H.R. 879) - Medicare Patient Access and Practice Stabilization Act (H.R. 1510) - Due Process Continuity of Care Act (S. 891) - Bipartisan Health Care Act (H.R. 1735/S. 779) - EARLY Minds Act (H.R. 786) - Reserving Patient Access to Accountable Care Act (S.2671/H.R. 5269) - RESULTS Act (2. 2749) - Medicare Sequester Exemption Bill (H.R. 483) - Health Care Efficiency Through Flexibility Act (H.R. 6160) - Strengthening Medicare for Patients and Providers Act (H.R. 6210) - Senior Savings Protection Act (S. 3300) - Access to New Community Health Opportunities and Recovery (ANCHOR) Act (S. 3522) - No Red Tape for Addiction Treatment Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":72463,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":83708,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"TULLY","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant - Rep. Kay Granger (R-Tx)","new":false},{"lobbyist":{"id":142935,"prefix":"ms","prefix_display":"MS.","first_name":"NATALIE","nickname":null,"middle_name":"ELAINE","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":146729,"prefix":null,"prefix_display":null,"first_name":"MEGAN","nickname":null,"middle_name":null,"last_name":"MORTIMER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":149012,"prefix":"ms","prefix_display":"MS.","first_name":"KATE","nickname":null,"middle_name":"WALLIS","last_name":"GILLIARD","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":145174,"prefix":"ms","prefix_display":"MS.","first_name":"ANNA","nickname":null,"middle_name":"SCHAUT","last_name":"WALDMAN","suffix":null,"suffix_display":null},"covered_position":"Intern - Sen. Kirsten Gillibrand (D-NY)","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"IMM","general_issue_code_display":"Immigration","description":"No Bill No. - Conrad 30 Waiver Program No Bill No. - H-1B Visa Proclamation No Bill No. - J-1 visas","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":83708,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"TULLY","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant - Rep. Kay Granger (R-Tx)","new":false},{"lobbyist":{"id":142935,"prefix":"ms","prefix_display":"MS.","first_name":"NATALIE","nickname":null,"middle_name":"ELAINE","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":72463,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145174,"prefix":"ms","prefix_display":"MS.","first_name":"ANNA","nickname":null,"middle_name":"SCHAUT","last_name":"WALDMAN","suffix":null,"suffix_display":null},"covered_position":"Intern, Sen. Kirsten Gillibrand (D-NY)","new":false},{"lobbyist":{"id":146729,"prefix":null,"prefix_display":null,"first_name":"MEGAN","nickname":null,"middle_name":null,"last_name":"MORTIMER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":149012,"prefix":"ms","prefix_display":"MS.","first_name":"KATE","nickname":null,"middle_name":"WALLIS","last_name":"GILLIARD","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"No Bill No. - Tax precentor incentives (H.R. 593) - Strengthening Pathways to Health Professions Act (H.R. 1026) - Primary Care Enhancement Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":72463,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"QUINN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":83708,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"TULLY","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant - Rep. Kay Granger (R-TX)","new":false},{"lobbyist":{"id":145174,"prefix":"ms","prefix_display":"MS.","first_name":"ANNA","nickname":null,"middle_name":"SCHAUT","last_name":"WALDMAN","suffix":null,"suffix_display":null},"covered_position":"Intern - Sen. Kirsten Gillibrand (D-NY)","new":false},{"lobbyist":{"id":142935,"prefix":"ms","prefix_display":"MS.","first_name":"NATALIE","nickname":null,"middle_name":"ELAINE","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146729,"prefix":null,"prefix_display":null,"first_name":"MEGAN","nickname":null,"middle_name":null,"last_name":"MORTIMER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":149012,"prefix":"ms","prefix_display":"MS.","first_name":"KATE","nickname":null,"middle_name":"WALLIS","last_name":"GILLIARD","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/22fe6ccc-5cd9-4e13-8026-5fb21276565c/","filing_uuid":"22fe6ccc-5cd9-4e13-8026-5fb21276565c","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/22fe6ccc-5cd9-4e13-8026-5fb21276565c/print/","filing_document_content_type":"text/html","income":null,"expenses":"125538.00","expenses_method":"B","expenses_method_display":"B","posted_by_name":"George Lyons, Jr.","dt_posted":"2026-04-14T11:42:15-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"25 Massachusetts Avenue, NW, Suite 700","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":311451,"url":"https://lda.gov/api/v1/registrants/311451/","house_registrant_id":40002,"name":"AMERICAN COLLEGE OF PHYSICIAN SERVICES, INC.","description":"Healthcare","address_1":"25 Massachusetts Avenue NW","address_2":"Suite 700","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GEORGE LYONS JR.","contact_telephone":"+1 202-261-4531","dt_updated":"2026-07-13T14:54:36.424626-04:00"},"client":{"id":183820,"url":"https://lda.gov/api/v1/clients/183820/","client_id":12,"name":"AMERICAN COLLEGE OF PHYSICIAN SERVICES, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"1999-12-30"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"ACPs 2026 First Quarter Lobbying Disclosure Report Senate Finance Committee Hearing: ACP advocated that Congress enacts FY2026 appropriations bills for funding Labor-HHS and several other federal agencies. These measures include advancing flexibilities for the use of telehealth, extending premium tax credits in the individual health insurance market, and reauthorizing and funding the National Health Service Corps and the Teaching Health Center Graduate Medical Education programs. We urged Congress to advance PBM reform legislation, reform prior authorization in Medicare Advantage plans. Expand Patient Access and Telehealth: We urged Congress to reintroduce and pass the Chronic Care Management Improvement Act. This legislation would have removed the cost sharing requirement for patients to access chronic care management services. We also support allowing the physician that performs chronic care management services to waive the requirement that the patient pay the 20 percent coinsurance fee associated with this service. Supported extending Pandemic-related telehealth flexibilities in the Continuing Resolution that passed Congress. Supported S. 1261, Connect for Health Act of 2025, to expand telehealth services under Medicare, by removing certain geographic restrictions starting October 1, 2025. Also supported H.R. 1899, Audio-Only Telehealth Access Act of 2025, to modify payment rules for certain covered medical items and services. We also supported the Protecting Rural Telehealth Access Act, a bill that would ensure that seniors may continue to access audio-only telehealth consults with their physician after this option expired in 2024. We supported the Preserving Telehealth, Hospital, and Ambulance Access Act, which would extend these flexibilities for two years until the end of 2026. We urged Congress to protect the public health infrastructure, recognize evidence-based science and preserve healthcare agency staffing to inform and protect the public from infectious disease and other health emergencies. Incidences of previously well-controlled, vaccine-preventable diseases, such as pertussis (whooping cough) and measles, are increasing in the United States. Vaccines are vital to our ability to prevent diseases that threaten public health, including novel diseases and future pandemics. We urged Congress to utilize the best possible scientific evidence to guide public health legislation. It is critical that public health leaders support evidence-based medicine, including the use of vaccines and other effective public health strategies that protect the public. ACP conducted a Hill Briefing on using scientifically driven, evidenced-based vaccines. Medicare Payments to Physicians: Met with House Doctors Caucus about Medicare payment reform, including draft language to be included in bills for a Medicare Economic Index inflationary updated to the physician fee schedule for physician practices. Supported and urged Congress to pass H.R. 8163, the Provider Reimbursement Stability Act, to enhance Medicare reimbursement stability for physicians by modernizing the Medicare Physician Fee Schedule. ACP focused on countering Surgeons on MPFS Final Rule Efficiency Adjustment -action alert and lobbying outreach. Extensive advocacy support for 2.5% reduction in the intra-service portion of practice expense for efficiency adjustment in Centers for Medicare and Medicaid Services 2026 final fee schedule rule. Primary care is excluded from adjustment. Support Value-Based Care: Urged reintroduction and support of the Value in Health Care Act of 2024. The bill provides a multi-year commitment to reforming care delivery by extending MACRAs 5 percent advanced alternative payment models (APM) incentives that expired at the end of 2024. ACP supported the Preserving Patient Access to Accountable Care Act which aligns with Colleges policy to support the transition to value-based payments through alternative payment models (APMs) that can accommodate a wide range of specialties, practice sizes, and unique patient populations. ACP supported this legislation as it would extend the incentive payments for qualifying physicians and other clinicians to participate in Medicare advanced APMs through payment year 2027 at an increased amount of 3.53 percent and would freeze the scheduled increase in qualifying thresholds. Pricing Transparency/Consolidation: Supported reintroducing and passing the Lower Costs, More Transparency Act, which are consistent with our policy and would improve access to and affordability of health care for patients. This legislation required disclosure of changes in hospital or health facility ownership to reveal when private equity firms acquire hospitals, larger physician practices or nursing homes, promoted price transparency among hospitals, health plans and pharmacy benefit managers and promoted site neutrality for Medicare and Medicare beneficiaries. We supported the Consolidated Appropriations Act, 2026 (CAA) (H.R. 7148), signed into law on February 3, 2026, that provides comprehensive funding for federal agencies through September 30, 2026. This legislation included PBM reforms. The reforms center on rebate pass‑through, increased transparency, standardized reporting, and expanded federal oversight. The Affordable Care Act (ACA) (P.L. 111-148, P.L. 111-152): Urged legislation to extend permanently the premium tax subsidies afforded under the ACA. Supported legislation by Senators Jeanne Shaheen and Tammy Baldwin, along with U.S. Congresswoman Lauren Underwood, the Health Care Affordability Act-bicameral legislation making permanent the ACAs enhanced premium tax credits for Marketplace coverage as extended through the Inflation Reduction Act. The law provides consumers with subsidies (premium tax credits) that lower costs for households with incomes between 100 percent and 400 percent of the federal poverty level (FPL). It expands the Medicaid program to cover all adults with income below 138 percent of the FPL. Urged Congress to include an extension of premium tax credits in OBBB. Urged Congress to include the enhanced PTCs in the CAA. FY2026 Appropriations/Agency Restructuring: Urged Congress to support funding for the Centers for Disease Control and Prevention's programs in the FY 2026 Labor, Health and Human Services, Education and Related Agencies Appropriations bill as well as funding shared evenly between the U.S. Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) to conduct public health research into firearm morbidity and mortality prevention. Advocated for funding for the Health Resources Services Administration (HRSA); Title Vi, Section 747, Primary Care Training and Enhancement (PCTE), Health Resources and Services Administration (HRSA); National Health Service Corps (NHSC); Agency for Healthcare Research and Quality (AHRQ); the Centers for Disease Control and Prevention's (CDC) Office on Smoking and Health (OSH). Urged Congress to include report language in the FY2026 Labor HHS appropriations bill to direct the GAO to conduct a study encompassing the last decade of CMS estimates of new and revised code utilizations. ACP believes CMS has overestimated utilizations, thus adversely affecting available funds in the Medicare physician fee schedule for other code usage. While the House and Senate bills included language, we prefer the stronger House version language and hope Congress will pass the FY26 Labor HHS bills. Also urged Congress to include report language in the FY2027 Labor HHS appropriations bill directing a study on extent G2211 add on codes and increases in fee schedule for primary care are being retained by hiring entities (hospitals, ACOs, private equity) versus the physicians. Supported S.Res.343, Recognizing the Important Work of the United States Preventive Task Force (USPTF). This resolution highlights the important role of the USPTF in making evidence-based recommendations about health promotion and the effectiveness of preventive health services and urges HHS to ensure current members on the task force serve their four-year terms to completion. Also sent a letter to House and Senate leadership urging the protection of the integrity of the United States Preventive Services Task Force (USPSTF), supported by the Agency for Healthcare Research and Quality (AHRQ). Primary Care and the Physician Workforce: Urged Congress to support the Resident Physician Shortage Reduction Act of 2025 (S. 2439/ H.R. 4731), which would increase the number of Medicare supported direct graduate medical education (DGME) and indirect medical education (IME) positions by 14,000 over seven years. ACP supported the Conrad State 30 and Physician Access Reauthorization Act, S. 709 and H.R. 1585, to allow states to sponsor foreign-trained physicians to work in medically underserved areas in exchange for a waiver of the physicians' two-year foreign residence requirement. We supported the Resident Education Deferred Interest (REDI) Act (S 942/HR 2028) that, if passed, will allow borrowers to qualify for interest-free deferment on their student loans while serving in a medical or dental internship or residency program. We supported the reauthorization and funding increases included for the Teaching Health Center Graduate Medical Education program, Community Health Center program and National Health Service Corps in the Continuing Resolution that was extended by Congress to September 30, 2025, and urged Congress for funding beyond the current extension. We urged Congress to note the success and importance of the Public Service Loan Forgiveness (PSLF) program and urged its preservation. Congress recognized the importance of recruiting and retaining highly qualified public service professionals when it enacted PSLF with bipartisan support. Supported legislation for the H-1Bs for Physicians and Healthcare Workforce Act, H.R. 7961. The bill's primary goal is to exempt healthcare professionals from a $100,000 H-1B visa filing fee. Prescription Drug Reform: Supported the Capping Prescription Costs Act, introduced by Senator Raphael Warnock. The legislation would lower prescription drug costs for millions of Americans by placing annual caps on out-of-pocket costs for prescription drugs at $2,000 for individuals and $4,000 for families with private insurance. Supported bipartisan Drug-price Transparency for Consumers (DTC) Act, a bill that would require price disclosures on advertisements for prescription drugs in order to empower patients and reduce Americans colossal spending on medications. The bill was introduced by Senators Dick Durbin and Chuck Grassley. ACP also supported the Saving Seniors Money on Prescriptions Act, H.R. 950, which aims to drive down the rising costs of prescription drugs for patients on Medicare by improving price transparency in Pharmacy Benefit Managers (PBMs) business practices. Urged Congress to reintroduce and pass: 1) the Lowering Drug Costs for American Families Act, to expand the number of prescription drugs which Medicare can negotiate under the Inflation Reduction Act from 20 to 50 starting in 2029; 2) the Medicare PBM Accountability Act, legislation aimed at lowering the costs of prescription drugs for seniors covered by Medicare Part D and Medicare Advantage plans; 3) the Increasing Access to Biosimilars Act of 2023, legislation which would encourage adoption of biosimilars in Medicare and improve biosimilar accessibility, by establishing a new pilot program - a voluntary, shared savings demonstration program - for providers of biosimilars in Medicare Part B; 4) the Cutting Copays Act, legislation which would eliminate cost-sharing for generic drugs for LIS beneficiaries, helping to incentivize the use of generic drugs; and the Drug Shortage Prevention Act of 2023, which would require that manufacturers of over-the-counter and prescription drugs notify Food & Drug Administration when they are unlikely to meet demand. ACP supported legislation, Drug-price Transparency for Consumers (DTC) Act, by Senators. Durbin and Grassley that requires Direct-to-Consumer advertisements for prescription drugs and biological products paid for by Medicare and Medicaid to include the list price or Wholesale Acquisition Cost (WAC) for a 30-month supply-which is the price set by manufacturers (and which is paid by uninsured patients, as well as the 50 percent of patients with high-deductible plans). ACP opposed H.R. 238, the Healthy Technology Act of 2025 (HTA). That Act would amend current law to clarify that artificial intelligence (AI) and machine learning technologies can qualify as a practitioner eligible to prescribe drugs if authorized by the state involved and approved, cleared, or authorized by the Food and Drug Administration. Family Caregiving: ACP supported the Family Caregiver Awareness, Resources, and Education (CARE) Partnerships Act, introduced by Rep. Dingell. This legislation would promote the health and well-being of family caregivers - those who provide the majority of long-term services and support (LTSS) in the United States - so that they can maintain their own health and their ability to continue providing essential care to patients who require LTSS. Administrative Burden: Urged Congress to reintroduce and pass the Improving Seniors' Timely Access to Care Act. This bipartisan legislation nearly passed last Congress and would reduce burdens associated with prior authorization in Medicare Advantage (MA) by: l) protecting beneficiaries from any disruptions in care due to prior authorization requirements as they transition between MA plans; 2) requiring all MA plans adopt electronic prior authorization capabilities to streamline the process for prior authorization approval; and 3) standardizing the process and procedures for reporting electronic prior authorization criteria to MA plans. Scope of Practice: Opposed the Equitable Community Access to Pharmacist Services Act, which would expand Medicare coverage to permanently include select services provided by a pharmacist. Clinical Labs: Supported the provision in H.R. 6366 that would delay payment reductions and data reporting periods for the Clinical Laboratory Fee Schedule under the Protecting Access to Medicare Act (PAMA). Legislation could improve patient access to laboratory tests used to diagnose, monitor, prevent, and manage diseases for Medicare beneficiaries. Cures 2.0: Reviewed and supported Cures 2.0 legislation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":37837,"prefix":null,"prefix_display":null,"first_name":"BRIAN","nickname":null,"middle_name":null,"last_name":"BUCKLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":60177,"prefix":null,"prefix_display":null,"first_name":"JARED","nickname":null,"middle_name":null,"last_name":"FROST","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":40417,"prefix":null,"prefix_display":null,"first_name":"SHUAN","nickname":null,"middle_name":null,"last_name":"TOMLINSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":104508,"prefix":null,"prefix_display":null,"first_name":"GEORGE","nickname":null,"middle_name":null,"last_name":"LYONS","suffix":"jr","suffix_display":"JR"},"covered_position":null,"new":false},{"lobbyist":{"id":150464,"prefix":null,"prefix_display":null,"first_name":"KORY","nickname":null,"middle_name":null,"last_name":"STUER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":9,"name":"President of the U.S."},{"id":1,"name":"SENATE"},{"id":39,"name":"State, Dept of (DOS)"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/d99ce340-6f20-4710-8ecc-fdd1165dfd9d/","filing_uuid":"d99ce340-6f20-4710-8ecc-fdd1165dfd9d","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/d99ce340-6f20-4710-8ecc-fdd1165dfd9d/print/","filing_document_content_type":"text/html","income":null,"expenses":"85668.00","expenses_method":"B","expenses_method_display":"B","posted_by_name":"Shari Erickson","dt_posted":"2026-04-14T11:47:59-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"25 Massachusetts Avenue, NW, Suite 700","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":2002,"url":"https://lda.gov/api/v1/registrants/2002/","house_registrant_id":32190,"name":"AMERICAN COLLEGE OF PHYSICIANS","description":null,"address_1":"25 Massachusetts Avenue, NW, Suite 700","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GEORGE LYONS JR.","contact_telephone":"+1 202-261-4531","dt_updated":"2026-07-13T17:53:37.650943-04:00"},"client":{"id":102673,"url":"https://lda.gov/api/v1/clients/102673/","client_id":12,"name":"AMERICAN COLLEGE OF PHYSICIANS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"1996-02-14"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"ACPs 2026 First Quarter Lobbying Disclosure Report Senate Finance Committee Hearing: ACP advocated that Congress enacts FY2026 appropriations bills for funding Labor-HHS and several other federal agencies. These measures include advancing flexibilities for the use of telehealth, extending premium tax credits in the individual health insurance market, and reauthorizing and funding the National Health Service Corps and the Teaching Health Center Graduate Medical Education programs. We urged Congress to advance PBM reform legislation, reform prior authorization in Medicare Advantage plans. Expand Patient Access and Telehealth: We urged Congress to reintroduce and pass the Chronic Care Management Improvement Act. This legislation would have removed the cost sharing requirement for patients to access chronic care management services. We also support allowing the physician that performs chronic care management services to waive the requirement that the patient pay the 20 percent coinsurance fee associated with this service. Supported extending Pandemic-related telehealth flexibilities in the Continuing Resolution that passed Congress. Supported S. 1261, Connect for Health Act of 2025, to expand telehealth services under Medicare, by removing certain geographic restrictions starting October 1, 2025. Also supported H.R. 1899, Audio-Only Telehealth Access Act of 2025, to modify payment rules for certain covered medical items and services. We also supported the Protecting Rural Telehealth Access Act, a bill that would ensure that seniors may continue to access audio-only telehealth consults with their physician after this option expired in 2024. We supported the Preserving Telehealth, Hospital, and Ambulance Access Act, which would extend these flexibilities for two years until the end of 2026. We urged Congress to protect the public health infrastructure, recognize evidence-based science and preserve healthcare agency staffing to inform and protect the public from infectious disease and other health emergencies. Incidences of previously well-controlled, vaccine-preventable diseases, such as pertussis (whooping cough) and measles, are increasing in the United States. Vaccines are vital to our ability to prevent diseases that threaten public health, including novel diseases and future pandemics. We urged Congress to utilize the best possible scientific evidence to guide public health legislation. It is critical that public health leaders support evidence-based medicine, including the use of vaccines and other effective public health strategies that protect the public. ACP conducted a Hill Briefing on using scientifically driven, evidenced-based vaccines. Medicare Payments to Physicians: Met with House Doctors Caucus about Medicare payment reform, including draft language to be included in bills for a Medicare Economic Index inflationary updated to the physician fee schedule for physician practices. Supported and urged Congress to pass H.R. 8163, the Provider Reimbursement Stability Act, to enhance Medicare reimbursement stability for physicians by modernizing the Medicare Physician Fee Schedule. ACP focused on countering Surgeons on MPFS Final Rule Efficiency Adjustment -action alert and lobbying outreach. Extensive advocacy support for 2.5% reduction in the intra-service portion of practice expense for efficiency adjustment in Centers for Medicare and Medicaid Services 2026 final fee schedule rule. Primary care is excluded from adjustment. Support Value-Based Care: Urged reintroduction and support of the Value in Health Care Act of 2024. The bill provides a multi-year commitment to reforming care delivery by extending MACRAs 5 percent advanced alternative payment models (APM) incentives that expired at the end of 2024. ACP supported the Preserving Patient Access to Accountable Care Act which aligns with Colleges policy to support the transition to value-based payments through alternative payment models (APMs) that can accommodate a wide range of specialties, practice sizes, and unique patient populations. ACP supported this legislation as it would extend the incentive payments for qualifying physicians and other clinicians to participate in Medicare advanced APMs through payment year 2027 at an increased amount of 3.53 percent and would freeze the scheduled increase in qualifying thresholds. Pricing Transparency/Consolidation: Supported reintroducing and passing the Lower Costs, More Transparency Act, which are consistent with our policy and would improve access to and affordability of health care for patients. This legislation required disclosure of changes in hospital or health facility ownership to reveal when private equity firms acquire hospitals, larger physician practices or nursing homes, promoted price transparency among hospitals, health plans and pharmacy benefit managers and promoted site neutrality for Medicare and Medicare beneficiaries. We supported the Consolidated Appropriations Act, 2026 (CAA) (H.R. 7148), signed into law on February 3, 2026, that provides comprehensive funding for federal agencies through September 30, 2026. This legislation included PBM reforms. The reforms center on rebate pass‑through, increased transparency, standardized reporting, and expanded federal oversight. The Affordable Care Act (ACA) (P.L. 111-148, P.L. 111-152): Urged legislation to extend permanently the premium tax subsidies afforded under the ACA. Supported legislation by Senators Jeanne Shaheen and Tammy Baldwin, along with U.S. Congresswoman Lauren Underwood, the Health Care Affordability Act-bicameral legislation making permanent the ACAs enhanced premium tax credits for Marketplace coverage as extended through the Inflation Reduction Act. The law provides consumers with subsidies (premium tax credits) that lower costs for households with incomes between 100 percent and 400 percent of the federal poverty level (FPL). It expands the Medicaid program to cover all adults with income below 138 percent of the FPL. Urged Congress to include an extension of premium tax credits in OBBB. Urged Congress to include the enhanced PTCs in the CAA. FY2026 Appropriations/Agency Restructuring: Urged Congress to support funding for the Centers for Disease Control and Prevention's programs in the FY 2026 Labor, Health and Human Services, Education and Related Agencies Appropriations bill as well as funding shared evenly between the U.S. Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) to conduct public health research into firearm morbidity and mortality prevention. Advocated for funding for the Health Resources Services Administration (HRSA); Title Vi, Section 747, Primary Care Training and Enhancement (PCTE), Health Resources and Services Administration (HRSA); National Health Service Corps (NHSC); Agency for Healthcare Research and Quality (AHRQ); the Centers for Disease Control and Prevention's (CDC) Office on Smoking and Health (OSH). Urged Congress to include report language in the FY2026 Labor HHS appropriations bill to direct the GAO to conduct a study encompassing the last decade of CMS estimates of new and revised code utilizations. ACP believes CMS has overestimated utilizations, thus adversely affecting available funds in the Medicare physician fee schedule for other code usage. While the House and Senate bills included language, we prefer the stronger House version language and hope Congress will pass the FY26 Labor HHS bills. Also urged Congress to include report language in the FY2027 Labor HHS appropriations bill directing a study on extent G2211 add on codes and increases in fee schedule for primary care are being retained by hiring entities (hospitals, ACOs, private equity) versus the physicians. Supported S.Res.343, Recognizing the Important Work of the United States Preventive Task Force (USPTF). This resolution highlights the important role of the USPTF in making evidence-based recommendations about health promotion and the effectiveness of preventive health services and urges HHS to ensure current members on the task force serve their four-year terms to completion. Also sent a letter to House and Senate leadership urging the protection of the integrity of the United States Preventive Services Task Force (USPSTF), supported by the Agency for Healthcare Research and Quality (AHRQ). Primary Care and the Physician Workforce: Urged Congress to support the Resident Physician Shortage Reduction Act of 2025 (S. 2439/ H.R. 4731), which would increase the number of Medicare supported direct graduate medical education (DGME) and indirect medical education (IME) positions by 14,000 over seven years. ACP supported the Conrad State 30 and Physician Access Reauthorization Act, S. 709 and H.R. 1585, to allow states to sponsor foreign-trained physicians to work in medically underserved areas in exchange for a waiver of the physicians' two-year foreign residence requirement. We supported the Resident Education Deferred Interest (REDI) Act (S 942/HR 2028) that, if passed, will allow borrowers to qualify for interest-free deferment on their student loans while serving in a medical or dental internship or residency program. We supported the reauthorization and funding increases included for the Teaching Health Center Graduate Medical Education program, Community Health Center program and National Health Service Corps in the Continuing Resolution that was extended by Congress to September 30, 2025, and urged Congress for funding beyond the current extension. We urged Congress to note the success and importance of the Public Service Loan Forgiveness (PSLF) program and urged its preservation. Congress recognized the importance of recruiting and retaining highly qualified public service professionals when it enacted PSLF with bipartisan support. Supported legislation for the H-1Bs for Physicians and Healthcare Workforce Act, H.R. 7961. The bill's primary goal is to exempt healthcare professionals from a $100,000 H-1B visa filing fee. Prescription Drug Reform: Supported the Capping Prescription Costs Act, introduced by Senator Raphael Warnock. The legislation would lower prescription drug costs for millions of Americans by placing annual caps on out-of-pocket costs for prescription drugs at $2,000 for individuals and $4,000 for families with private insurance. Supported bipartisan Drug-price Transparency for Consumers (DTC) Act, a bill that would require price disclosures on advertisements for prescription drugs in order to empower patients and reduce Americans colossal spending on medications. The bill was introduced by Senators Dick Durbin and Chuck Grassley. ACP also supported the Saving Seniors Money on Prescriptions Act, H.R. 950, which aims to drive down the rising costs of prescription drugs for patients on Medicare by improving price transparency in Pharmacy Benefit Managers (PBMs) business practices. Urged Congress to reintroduce and pass: 1) the Lowering Drug Costs for American Families Act, to expand the number of prescription drugs which Medicare can negotiate under the Inflation Reduction Act from 20 to 50 starting in 2029; 2) the Medicare PBM Accountability Act, legislation aimed at lowering the costs of prescription drugs for seniors covered by Medicare Part D and Medicare Advantage plans; 3) the Increasing Access to Biosimilars Act of 2023, legislation which would encourage adoption of biosimilars in Medicare and improve biosimilar accessibility, by establishing a new pilot program - a voluntary, shared savings demonstration program - for providers of biosimilars in Medicare Part B; 4) the Cutting Copays Act, legislation which would eliminate cost-sharing for generic drugs for LIS beneficiaries, helping to incentivize the use of generic drugs; and the Drug Shortage Prevention Act of 2023, which would require that manufacturers of over-the-counter and prescription drugs notify Food & Drug Administration when they are unlikely to meet demand. ACP supported legislation, Drug-price Transparency for Consumers (DTC) Act, by Senators. Durbin and Grassley that requires Direct-to-Consumer advertisements for prescription drugs and biological products paid for by Medicare and Medicaid to include the list price or Wholesale Acquisition Cost (WAC) for a 30-month supply-which is the price set by manufacturers (and which is paid by uninsured patients, as well as the 50 percent of patients with high-deductible plans). ACP opposed H.R. 238, the Healthy Technology Act of 2025 (HTA). That Act would amend current law to clarify that artificial intelligence (AI) and machine learning technologies can qualify as a practitioner eligible to prescribe drugs if authorized by the state involved and approved, cleared, or authorized by the Food and Drug Administration. Family Caregiving: ACP supported the Family Caregiver Awareness, Resources, and Education (CARE) Partnerships Act, introduced by Rep. Dingell. This legislation would promote the health and well-being of family caregivers - those who provide the majority of long-term services and support (LTSS) in the United States - so that they can maintain their own health and their ability to continue providing essential care to patients who require LTSS. Administrative Burden: Urged Congress to reintroduce and pass the Improving Seniors' Timely Access to Care Act. This bipartisan legislation nearly passed last Congress and would reduce burdens associated with prior authorization in Medicare Advantage (MA) by: l) protecting beneficiaries from any disruptions in care due to prior authorization requirements as they transition between MA plans; 2) requiring all MA plans adopt electronic prior authorization capabilities to streamline the process for prior authorization approval; and 3) standardizing the process and procedures for reporting electronic prior authorization criteria to MA plans. Scope of Practice: Opposed the Equitable Community Access to Pharmacist Services Act, which would expand Medicare coverage to permanently include select services provided by a pharmacist. Clinical Labs: Supported the provision in H.R. 6366 that would delay payment reductions and data reporting periods for the Clinical Laboratory Fee Schedule under the Protecting Access to Medicare Act (PAMA). Legislation could improve patient access to laboratory tests used to diagnose, monitor, prevent, and manage diseases for Medicare beneficiaries. Cures 2.0: Reviewed and supported Cures 2.0 legislation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":53637,"prefix":null,"prefix_display":null,"first_name":"SHARI","nickname":null,"middle_name":null,"last_name":"ERICKSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141127,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"PUGACH","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":146685,"prefix":null,"prefix_display":null,"first_name":"VY","nickname":null,"middle_name":null,"last_name":"OXMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":9,"name":"President of the U.S."},{"id":1,"name":"SENATE"},{"id":39,"name":"State, Dept of (DOS)"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/b5326e89-bbc1-41d2-8020-6a9817c92b9d/","filing_uuid":"b5326e89-bbc1-41d2-8020-6a9817c92b9d","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/b5326e89-bbc1-41d2-8020-6a9817c92b9d/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-04-15T08:09:07-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/b5326e89-bbc1-41d2-8020-6a9817c92b9d/","filing_uuid":"b5326e89-bbc1-41d2-8020-6a9817c92b9d","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/b5326e89-bbc1-41d2-8020-6a9817c92b9d/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-04-15T08:09:07-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/b5326e89-bbc1-41d2-8020-6a9817c92b9d/","filing_uuid":"b5326e89-bbc1-41d2-8020-6a9817c92b9d","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/b5326e89-bbc1-41d2-8020-6a9817c92b9d/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-04-15T08:09:07-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/b5326e89-bbc1-41d2-8020-6a9817c92b9d/","filing_uuid":"b5326e89-bbc1-41d2-8020-6a9817c92b9d","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/b5326e89-bbc1-41d2-8020-6a9817c92b9d/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-04-15T08:09:07-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/b5326e89-bbc1-41d2-8020-6a9817c92b9d/","filing_uuid":"b5326e89-bbc1-41d2-8020-6a9817c92b9d","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/b5326e89-bbc1-41d2-8020-6a9817c92b9d/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-04-15T08:09:07-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/b5326e89-bbc1-41d2-8020-6a9817c92b9d/","filing_uuid":"b5326e89-bbc1-41d2-8020-6a9817c92b9d","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/b5326e89-bbc1-41d2-8020-6a9817c92b9d/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-04-15T08:09:07-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}]}